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ABSTRACT 
 Neuropeptide FF is an endogenous RF-amide with two receptor subtypes originally 
described as having anti-opioid characteristics.  While peptide work helped to elucidate key 
features for targeting the subtypes of the neuropeptide FF receptor, non-peptide small molecules 
offer a more refined tool to discover features that affect selectivity and affinity.  Improvements in 
small molecule ligands for neuropeptide FF support lead development and offer a clearer 
understanding of the binding pocket of each receptor subtype.  Previous work on the lead 4-
anilindopiperidine structure clarified a key feature between agonist and antagonist behavior.  
Early modifications of substituents of the piperidine nitrogen were tolerated and created selective 
ligands.  Therefore, syntheses of aliphatic and aromatic substitutions of the piperidine nitrogen of 
a 4-anilinopiperdine lead molecule were conducted.  In vitro evaluation of the novel compounds 
was conducted through a collaborator.  Binding affinities of the novel compounds were 
determined through displacement of a radioligand ([
3
H]-NPVF for NPFF1 receptors and [
3
H]-
EYF for NPFF2 receptors) and were conducted for each subtype.  Though some of the 
compounds, such as cycloheptylmethyl substituted analog, did not bind within the limits of the 
assay to either subtype, other compounds, such as the cyclopropylmethyl and methylindole 
derivatives, did bind.  The cyclopentylmethyl and methylindole derivatives offered a weak 
preference for the second subtype.   
iii 
 
 The formalin assay offers an opportunity to evaluate neuropeptide FF in a tonic pain model.  In 
summation, selective non-peptide ligands for each neuropeptide FF receptor offer a key tool to 
elucidating the evolving role of neuropeptide FF and creating potentially useful therapeutics in 
the future.        
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CHAPTER 1 
INTRODUCTION 
 
With the discovery and isolation of neuropeptide FF (NPFF) from bovine brain in 1985
1
, 
NPFF (FLFQPQRFa) has been linked to a variety of biological activities.  It is part of a family of 
peptides that have a dipeptide Arg-Phe-NH2 at their C-terminal, known as RF-amides
2
.  Other 
members of the family include prolactin-releasing peptides, kisspeptin/metastin and 
QRFP/P518/26RFa
3
.  Two subtypes of the G protein-coupled receptor for NPFF exist and have 
been identified as NPFF1 and NPFF2
4
.  Endogenous peptides NPSF and NPVF show preference 
for NPFF1 subtype in vivo
5
, while endogenous peptide NPFF prefers NPFF2 subtype
6
.  Table 1 
describes the sequences of NPSF, NPVF, and NPFF for human, bovine, mouse, and rat species
6
.  
NPFF1 and NPFF2 are distributed throughout the body with NPFF2 present in both the spine and 
brain, while NPFF1 appears only in the brain
7, 8
.
 
2 
 
Table 1 Sequence of endogenous neuropeptide FF and RF-related peptides 
 
a
Note that NPSF has been used in the literature to describe both an eight amino acid short version 
of NPAF and a 37 amino acid extended version of rat RFRP-1.  NPFF: neuropeptide FF; RFRP: 
RF-related peptide. Reproduced with permission from 
6
. 
 Although initially described solely as an anti-opioid system
9, 10
, NPFF through its 
interaction with its cognate receptors exhibits a myriad of pharmacological effects.  The complex 
nature of the NPFF pharmacology depends on which subtype is targeted, the route of 
administration, and opioid activity
11
.  For example, the anti-opioid properties of NPFF are seen 
when the route of administration is intracerebroventricular (i.c.v.); yet, if the route of 
administration is changed to intrathecal (i.t.), NPFF has shown to extend morphine-induced 
analgesia
12
.  In addition to affecting the opioid system, NPFF has been connected to pain 
modulation, changes in arterial blood pressure
8
, regulation of monoamine systems
8
, reduction in 
food intake
13, 14
 and regulation of core temperature
15, 16
.  The majority of the pharmacological 
functions have been discovered through several groups’ efforts to create peptide ligands for 
NPFF1 and NPFF2 receptors. 
  
3 
 
Initial work in the 1990s observed the importance of the N-terminal amino acids of 
endogenous NPFF by the creation of modified peptide analogs
17
.  It was initially shown that the 
N-terminal amino acid was responsible for high affinity binding.  Affinity radioligands for NPFF 
receptors were created by modifying peptides (DYLMEFQPQRF- and YLFQPQRF-amide)
18
.  
Peptide synthesis and subsequent evaluation produced both agonist and antagonists.  BIBP3226 
was initially described as a neuropeptide Y (NPY) Y1 receptor antagonist
19, 20
.  It also proved to 
have pharmacological activity at NPFF receptors both in vitro and in vivo.  For example, in vitro 
NPY-derived ligands BIBP3226 (Ki ≈ 100nM for NPFF2 receptor) and GR231118 (Ki = 50-70 
nM for NPFF2 receptor) acted as antagonist, and agonist, respectively
21
.  In vivo BIBP3226 was 
able to offset hypothermic effects of cerebrally injected NPFF and NPVF in mice and prevent 
anti-morphine actions of NPFF in mouse tail-flick assay
22
.  By contrast, it appears that the 
endogenous peptide NPVF is selective for NPFF1 versus NPFF2 receptors
5
.  Likewise, peptide 
VPNLPQRF-NH2 shows strong selectivity for the NPFF1 receptor, while peptide 
EFWSLAAPQRF-NH2 has strong selectivity for the NPFF2 receptor (Table 2)
23
. 
Table 2 Peptides with selectivity for NPFF1 or NPFF2 
Peptide Sequence Ki for NPFF1 (nM) Ki for NPFF2 (nM) 
VPNLPQRF-NH2 0.6 17.4 
EFWSLAAPQRF-NH2 20.8 0.21 
Data from 
23
. 
 The dipeptide known as RF9 is a nonselective antagonist for the NPFF receptors (Figure 
1)
24
.  RF9 can prevent NPFF-induced hypothermia
25
 and does not lower body temperature itself.  
RF9 does appear to exert inhibitory effects on NPFF agonist-induced changes in body 
temperature and nociceptive tests, yet does not affect these changes when administered alone
26
. 
4 
 
 
Figure 1 Nonselective dipeptide neuropeptide FF antagonist, RF9 
 
 Another interesting study showed that dansylated GSRF-NH2 and dansylated PQRF-NH2 
acted as agonists, while dansylated GSR-NH2 and dansylated PQR-NH2 acted as antagonists on 
NPFF receptors
16, 27
.  More recently, the peptide dNPA (D-Asn-Pro-(NHMe)Ala-Phe-Leu-Phe-
Gln-Pro-Gln-Arg-Phe-NH2) was found to be a selective NPFF2 agonist
28
. 
 Found mainly in the patent literature, non-peptide small-molecule NPFF ligands offer a 
different viewpoint for probing the NPFF receptors and pharmacology of the system as a whole.  
One of the main benefits of these small-molecule ligands is their ability to better define the 
active site of NPFF1 or NPFF2 receptors; likewise, selectivity and affinity can be improved 
through relatively minor modifications in a parent structure.  The majority of the small molecules 
described in the patent literature feature a guanidine functionality.  For instance, Acadia 
Pharmaceuticals has published structures featuring hydrazine/guanidine functionality; Actelion 
Pharmaceuticals and Synaptic Pharma Group each published similar core structures with a 
guanidine moiety attached directly to a heterocycle (Figure 2 & 3).  In contrast, two different 
Japanese patents show molecules that do not have a guanidine moiety but still retain their affinity 
for NPFF system. 
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Figure 2 Actelion Pharmaceuticals compounds with single digit nanomolar IC50 at NPFF1 
receptor 
 
Figure 3 Synaptic Pharma Group NPFF core structures 
 
 Taisho Pharmaceutical, a Japanese company, has a patent
29
 that describes compounds 
with IC50 values between 30 and 300 nM.  The IC50 values are for rat NPFF2 receptors in vitro.  
The core structure of their compounds is represented by a fused imidazole-pyrazine with indole 
and piperidine substitutions (Figure 4). 
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Figure 4 Core structure for Taisho Pharmaceutical NPFF2 compounds 
 
R= 
 
 
  
  
Examples of substitutions (not inclusive) from Taisho Pharmaceutical
29
. 
 The structure-activity relationship (SAR) suggests that varying the carbon linker between 
the piperidine nitrogen and a substitution is tolerated within the reported IC50 values (Figure 5). 
Figure 5 Changes in carbon linker between piperidine nitrogen and alkyne moiety 
 
7 
 
 Likewise, methylation at various positions of indole ring maintains activity within the 30-
300 nM range (Figure 6).  Attachment of indole-substituted electron-withdrawing or electron-
donating groups also preserves activity (Figure 6). 
Figure 6 Various substitutions on the indole ring 
 
 Changing the piperidine ring nitrogen substituent to a secondary or tertiary amine, or 
having an ether linkage still upholds IC50 values in the reported range.  Replacing the indole ring 
with other heterocyclic ring systems also keeps the IC50 values between 30 and 300 nM.  While 
Taisho Pharmaceutical describes over 90 compounds in their patent, specific IC50 values for 
individual compounds are not disclosed.  Therefore, it is difficult to fully appreciate and 
construct a complete SAR. 
8 
 
 Kyowa Hakko Kogyo Company reports their NPFF small molecules at a fixed 
concentration 3 µM and as a percentage binding of rat NPFF receptor
30
.  These molecules have 
an indole ring with a four carbon spacer attached to a pyrrolidine as their common core 
structure (Figure 7). 
 Figure 7 Core Structure of Kyowa Hakko Kogyo NPFF small molecule ligands 
 
R R1 
20 
 
 
 
21 
  
22 
 
 
This is not an inclusive list of R and R1 substitutions included in the patent
30
. 
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 The best compound disclosed has a branched biphenyl in the 3-position and a 
cyclooctane ring in addition to the core structure (Figure 8).  This compound exhibits 100% 
binding at 3µM.  Interestingly, replacing the cyclooctane ring with a cyclohexane ring reduces 
the percent binding by almost 40%, to 61% at rat NPFF receptor (Figure 9).  Changing a 
cyclohexane to a cycloheptane ring improves the percentage binding to approximately 94%.  
Another interesting finding from the SAR study is the importance of the linker between the 
indole and pyrrolidine, switching from a four-carbon linker to a three-carbon linker drops the 
activity from 100% to 41% binding at 3 µM. 
Figure 8 Best Kyowa Hakko Kogyo compound  
 
100% binding at 3 µM at rat NPFF receptor. 
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Figure 9 Different Ring Sizes in Kyowa Hakko Kogyo Compounds 
 
Varying ring size from an eight- to six- member ring dramatically decreases percent binding to 
rat NPFF receptor. 
 
 The change in linker does not always decrease percentage binding; in fact, reducing the 
linker from a four- to three-carbon chain improves percentage binding.  While certain SAR 
features are clearer with Kyowa Hakko Kogyo compounds, further clinical development seems 
unlikely due to high lipophilicity of these compounds.  Delivery, drug-drug interactions and 
plasma-protein binding all seem plausible barriers to development of these NPFF small 
molecules.  Some of these challenges may have already been addressed, as the patent reports that 
in vivo hot plate and tail-flick assays were performed; however, it was unclear which compound 
or compounds were tested. 
 Acadia Pharmaceuticals published selective NPFF2 receptor agonists with a hydrazine-
guanidine core structure
31
.  They report their data as pEC50 and percentage efficacy for NPFF1 
and NPFF2 receptors, although they do not specify from which species the NPFF receptors are 
derived.  According to the patent
32
, efficacy is the percentage maximal response compared with 
11 
 
the maximum response elicited by endogenous neuropeptide FF; therefore, pEC50 is the negative 
log(EC50) and the EC50 is the molar concentration that produces 50% maximal response.  A 
variety of substitutions of the hydrazine-guanidine core provided active and selective 
compounds.  Of the compounds tested in vitro at both NPFF1 and NPFF2 receptors, two were 
taken on further to in vivo models of pain (Figure 10). 
Figure 10 Compounds from Acadia Pharmaceuticals 
 
Compounds 1045, 3093, and 3099 are selective NPFF2 receptor agonists; Compounds 3093 and 
3099 were successful at reducing tactile allodynia in spinal nerve ligation model of pain in rats.  
 
 Compound 25 was tested in thermal hyperalgesia assay and chronic constriction injury 
assay
33, 34
 where it showed dose-dependent reduction in hyeralgesia.  Interestingly, compound 24 
with a dichlorobenzylidene fragment was not effective in multiple in vivo models; yet compound 
25 with the dibromobenzylidene residue was effective in some of the same in vivo models of 
pain and inflammation.  In addition, compound 26 with a chlorotrifluromethylbenzylidene 
moiety was also effective in in vivo models. 
12 
 
 Actelion Pharmaceuticals disclosed compounds exhibiting nanomolar binding to NPFF1 
receptor expressed in Chinese hamster ovary (CHO) cells.  The core structure is a 
tetrahydroquinazoline with a guanidine at the 2-position and a methyl at the 4-position
35
.  The 
disclosed compounds with the 2-guanidine, 4-methyl tetrahydroquinazoline core structure and an 
aliphatic substitution of at least two carbons at the 6-position have single-digit nanomolar 
binding affinities (Figure 2).  In a second patent
36
, Actelion Pharmaceuticals describe 
compounds having a tetrahydrobenzothiazole with a guanidine at the 2-position.  Nanomolar 
binding for NPFF1 receptor is reported for several of their best compounds.  Substitutions at the 
5-, 4-, and 6-position were explored and are tolerated maintaining single-digit binding affinity.  
A few interesting SAR features were identified through exploration of substitutions around the 
tetrahydrobenzyl portion of the compound.  For example, a tert-butyl group at the 6-position 
affords 10 nM affinity, yet moving it to the 4-position creates an even stronger binding affinity at 
2 nM (Figure 11). 
Figure 11 Positional Isomers from Actelion Pharmaceuticals 
 
Changing a tert-butyl substitution from the 6- to the 4-position increases NPFF1 receptor binding 
affinity. 
 Similarly, changing a dimethyl substitution from the 6-position to the 5-position of the 
tetrahydrobenzothiazole ring improves the binding from 4 to 2 nM, while changing a methyl, 
ethyl di-substitution from the 4- to the 5-position increases the binding from 5 to 0.2 nM (Figure 
12). 
13 
 
Figure 12 Explorations of Tetrahydrobenzothiazole Ring Substitutions 
 
Changes from the 6- or 4-position to the 5-position on the tetrahydrobenzothiazole ring improves 
binding affinity at NPFF1 receptor. 
 
 While these data prove interesting, it is difficult to know how selective the compounds 
from Actelion Pharmaceuticals are, since no NPFF2 receptor data are presented in the patents. 
 Synaptic Pharma Group describes compounds that are agonists, antagonists and mixed 
agonist/antagonists at NPFF1 and NPFF2 receptors.  They describe compounds in both rat and 
human NPFF1 and NPFF2 receptor binding.  The core structure of their compounds are a 
quinazoline with a guanidine at the 2-position and a methyl substitution at the 4-position
37, 38
 
(Figure 3).  Aliphatic and aromatic substitutions at the 6- and 7-position were explored.  Larger 
aliphatic or bicyclic substitutions seem to create compounds that bind to NPFF1 and NPFF2 
receptors without much selectivity; while smaller substitutions at the 6- or 7-position create 
compounds with at least tenfold selectivity between the two receptor subtypes.  The company 
describes their compounds as agonist or antagonist according to intrinsic activity and Ki values: 
an agonist has a >15% intrinsic activity, an antagonist has ≤15% intrinsic activity and a Ki value 
≤1.2 µM at the rat NPFF receptors39.  According to Synaptic Pharma Group’s claims, 
compounds that act as an agonist at NPFF1 and NPFF2 receptors would be suitable for treatment 
14 
 
of incontinence and pain; likewise, compounds that as NPFF1 and NPFF2 receptor antagonists 
could have pro-opioid effects.  Additionally, compounds that are NPFF1 receptor agonists might 
be used to treat obesity, according to the company’s patents39. 
 Despite a variety of small molecules published in patent literature, a straightforward SAR 
is still absent.  Lipophilic substitutions, a nitrogen-containing heterocycle, and guanidine 
substitution are common to most but not all of structures.    
 
15 
 
 
CHAPTER 2 
PRELIMINARY DESIGN OF NON-PEPTIDE NEUROPEPTIDE FF LIGANDS 
 
 Initial work on non-peptide ligands for neuropeptide FF began with an assessment of the 
structure-activity relationships (SAR) learned from neuropeptide FF peptide work
40
 and lessons 
learned in the opioid field
41-43
.  For instance modifications on both the C-terminal and N-terminal 
of endogenous neuropeptide FF lead to the conclusions that the N-terminal was responsible for 
high affinity binding
17
 while the C-terminal showed the importance of the guanidine and 
aromatic functionalities
40, 44
.  Furthermore work within opioid analgesics demonstrates the 4-
anilindopiperdine (Figure 13) to be a relevant and chemically feasible starting point for a non-
peptide neuropeptide FF ligand
45
.  Overlay of the 4-anilindopiperdine structure shows that key 
features could be aligned with endogenous NPFF C-terminal features of a guanidine and an 
aromatic ring (Figure 14)
40
. These facts guided the design and evaluation of various portions of 
the 4-anilindopiperdine core to optimize affinity and selectivity for both NPFF receptor subtypes. 
Figure 13 Representative 4-anilindopiperide opioid analgesics, Fentanyl 
16 
 
Figure 14 Alignment of guanidine substituted 4-anilinopiperdine and neuropeptide FF 
 
The guanidine substitution aligns with the arginine residue of the peptide and the aromatic rings 
align with phenylalanine rings of the peptide.
40
 
   
 Work began on the 4-anilindopiperdine core with modifications occurring in three 
locations: the aniline moiety (A), the nitrile moiety (B), and the piperidine nitrogen (C) (Figure 
15).  
Figure 15 Three key locations of modification for non-peptide neuropeptide FF ligands 
 
A 
C 
B 
34 
17 
 
 Starting with the aniline moiety (A) modifications explored the space of the binding 
pocket near the aniline portion by adding electron-withdrawing groups such as halides (F and Cl) 
or electron-donating groups such as methoxyl in various substitution patterns.   
 These changes did not improve selectivity between NPFF1 and NPFF2 receptors but gave 
affinity in the hundreds nanomolar range in a competitive radioligand binding assay
46
.  In 
another modification the aniline moiety was replaced with a naphthalene-1-amine.  This structure 
had improved binding at NPFF1 compared to earlier structures and had a ten-fold selectivity at 
NPFF1 compared to NPFF2.  To see if the aniline moiety was necessary, compounds were 
synthesized without the aniline.  The resulting compounds showed weak binding to NPFF2 and 
did not displace the radioligand within the limits of the assay for NPFF1.  To further understand 
if the nitrogen of the aniline was necessary for binding an analog was synthesized with a benzyl 
substitution.  Likewise, instead of a naphthalene-1-amine, a naphthalene analog was also 
synthesized.  In both cases, loss of the nitrogen did not decrease binding affinity but switched the 
relative selectivity; in other words the analog with the nitrogen was selective for NPFF1 receptor 
while the analog without the nitrogen was selective for NPFF2 receptor (Figure 16).  Some 
changes to the aniline moiety were also combined with or caused changes in the nitrile 
(guanidine) portion of the core structure.  For instance, a 2-phenyl-benzylimidazole substitution 
attempted to mimic the aniline portion but also rigidify the guanidine/nitrile portion of the core 
structure.  The resulting compound yielded no selectivity between the receptor subtypes and poor 
binding (five- to six-thousand nanomoloar).  Similarly having an amide bond in lieu of the 
aniline as well as a medium (4-carbon) chain to the guanidine moiety gave poor binding at 
NPFF2 and no binding at NPFF1.  In another attempt to explore the importance of the aniline an 
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amide bond was introduced; this structure also had a 4-carbon spacer to the guanidine.  The 
changes did not lead to a selective ligand and it had poor binding affinity. 
 Figure 16 Modifications in aniline moiety of core structure 
  
 Modifications of aniline and nitrile/guanidine moieties together did not yield favorable 
results.  To examine the potential benefits of modifying the nitrile/guanidine (Figure 15, B) a 
variety of changes were made.   One change was to see if a permanent charge would improve 
affinity or selectivity as the guanidine is ionized at physiologically relevant pHs.  The 
permanently charged compound did not bind within the limits of the assay.  Another change 
made was to create a reverse amide; this compound gave hundred-fold selectivity for NPFF1 
versus NPFF2 receptor (Figure 17).   
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Figure 17 Reverse amide NPFF ligand 
 
Initially the core structure contained a guanidine group directly attached to the piperidine ring, 
and compounds were designed to contain a spacer between the piperidine and guanidine groups. 
The most logical compound incorporated arginine, as this amino acid contained a guanidine 
moiety.  The arginine derivative provided ten-fold selectivity toward the NPFF1 receptor; while 
eliminating the primary amine leaving only a 3-carbon spacer abolished the selectivity between 
NPFF1 and NPFF2 receptors.  Moreover increasing the spacer to 4- or 5- carbons did not confer 
selectivity or improve affinity.  In contrast, decreasing the spacer between the piperidine ring and 
the guanidine moiety to a glycine amino acid giving a one carbon spacer or moving to a two 
carbon spacer did improve selectivity for NPFF1 receptor over NPFF2 receptor (Figure 18).  
Rigidifying the linker from a simple carbon chain to a benzyl linker did not enhance selectivity 
or affinity.   Attempts to alter the guanidine moiety to a more orally bioavailable and 
physiologically acceptable structure did not result in complete loss of affinity but failed to confer 
greater than ten-fold selectivity for NPFF1 versus NPFF2 receptors (Figure 19). 
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Figure 18 Changing from arginine to glycine linker to guanidine moiety 
 
Figure 19 Alternations of the guanidine moiety 
 
 Initially the arginine residue at position B of the core structure was kept constant while 
modifications of the piperidine-ring nitrogen were explored.  For example, switching from a 
benzyl to a methyl group provided an analog with no activity at the maximal concentration of the 
binding assay.  Likewise, extending the linker from one carbon to two carbons between the 
piperidine nitrogen and the benzyl ring did not improve selectivity.  A ten-fold selectivity for 
NPFF1 receptor was achieved when the piperidine nitrogen was substituted with a bi phenyl 
moiety.  Finally a naphthalene substitution improved binding affinity at both receptors but did 
not improve selectivity between the receptor subtypes (Figure 20).    In a parallel series no 
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spacer was utilized to separate the guanidine moiety from the core piperidine structure.  
Expanding the space by two carbons between the piperidine nitrogen and the benzyl moiety did 
not improve selectivity or affinity compared to the simple benzyl substituted compound.  
Likewise, changing to a methyl gave no affinity for either receptor even at the maximal 
concentration of the binding assay. 
 Since earlier work at position B of the core showed that a glycine spacer from the core 
structure to the guanidine moiety provided good affinity, this was utilized as the new standard for 
the remaining modifications to substitutions of the piperidine nitrogen.  For instance an ethyl 
benzyl substitution gave a ten-fold selectivity to NPFF2 receptor versus NPFF1 receptor.  The 
naphthalene substitution gave good affinity but did not confer selectivity between the two 
receptor subtypes.  Moreover, a positional isomer of the naphthalene substitution also had good 
affinity but selectivity again was not improved.  Creating a mimic for the naphthalene with an E-
cinnamyl substitution followed the trend of good affinity, but no distinct selectivity between 
receptor subtypes (Figure 21). 
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Figure 20 Early substitutions at the piperidine nitrogen with arginine-guanidine core 
structure 
 
 
Figure 21 Glycine-guanidine core structure with various piperidine nitrogen substitutions 
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 Other modifications include mono- and di-substituted aromatic substitutions.  
Compounds containing mono-substitutents at para-, ortho-, and meta-positions were 
synthesized.  Electron-withdrawing groups at the para-position had good affinity for NPFF1 and 
NPFF2 receptors.  Electron-withdrawing group at the ortho-position maintained good affinity 
(hundreds nanomolar) but did not show selectivity.  An electron-withdrawing group at the meta-
position actually decreased affinity by ten-fold.  However, an electron-donating group at the 
meta-position kept affinity in the hundred nanomolar range.  Di-substitutions on the aromatic 
ring off the piperidine nitrogen gave good affinity in the case of meta-, para-substitution pattern.  
In the case of both meta-positions being occupied a ten-fold selectivity was afforded to NPFF2 
versus NPFF1 receptors. 
 A ten-fold selectivity was also produced when the position of the nitrogen on the 
piperidine was changed so the aniline and guanidine moieties were now only one carbon 
compared to the normal two carbons away (Figure 22).  The isoelectric replacement of the 
nitrogen with a double-bond did not enhance the affinity or selectivity.  Likewise changing from 
benzene to pyridine did not improve selectivity or affinity for the NPFF receptors. 
Figure 22 Change in position of nitrogen of piperidine ring to aniline/guanidine portion of 
core structure 
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 Positional isomers of the pyridine substitution may offer different perspective and have 
been synthesized.  In contrast, a cyclohexane replacement of the benzene ring provided a ten-fold 
selectivity toward NPFF2 compared to NPFF1 receptors.  The goal of this work was to explore 
further aliphatic substitutions of various sizes to better understand their potential impact on 
affinity and selectivity in the lead template molecule. 
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CHAPTER 3 
SYNTHESIS OF NON-PEPTIDE NPFF LIGANDS 
 Early on in our structure-activity relationship studies, the 4-anilindopiperidine scaffold 
was determined to provide a chemically accessible scaffold as well as have three clear regions 
from which to explore various modifications and structural alterations.  Figure 15 describes 
these regions as the aniline (region A), the nitrile which was transformed into a guanidine (region 
B), and the piperidine nitrogen (region C).  Each region offered an opportunity to investigate 
which modifications may help or hinder our goal of improving binding affinity and selectivity 
between NPFF1 and NPFF2receptors.  Initially, the aniline moiety was removed; this provided an 
analog with 10 µM affinity at NPFF1 receptor and 3372 nM at NPFF2.  Likewise changing from 
a secondary amine to an amide gave 1525 nM affinity at NPFF1 and 4034 nM affinity at 
NPFF2.  After the time of the work described below, other changes were made to the aniline 
moiety of our scaffold.  Substitutions off the aromatic ring included electron withdrawing groups 
such as halogens (F or Cl) as well as electron donating groups such as (methoxy), for mono- or 
di-substituted rings the meta position was favored over thepara position.  For instance di-
chloroaniline substitution yielded an analog with 191 nM at NPFF1 and 409 nM at 
NPFF2.  While mono-substituted para-fluroaniline, gave 447 nM at NPFF1 and 1116 nM at 
NPFF2.  Similarly, the di-methoxy substituted aniline (with both substitutions at 
the metapositions) gave a compound with 114 nM at NPFF1 and 987 nM at NPFF2.  
Changing the substitution from aniline to a larger naphthyl and amino-naphthyl substituted 
scaffold proved interesting.  Switching to the amino-naphthyl substituted scaffold gave 94 nM at 
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NPFF1 and 309 nM at NPFF2 while removing the nitrogen and substituting with a naphthyl 
group gave binding affinities of 112 nM at NPFF1 and 30 nM at NPFF2.  The removal of the 
nitrogen effectively reversed affinity between NPFF1 and NPFF2. 
 
            The next region we explored was the guanidine region including the linkage between the 
guanidine moiety and the piperidine ring.  Changes in the linker length between the guanidine 
portion and the piperidine portion were varied from 1 carbon to 5 carbons.  The best compounds 
had either a two-carbon glycine-type linkage or three-carbon arginine-type 
linkage.  Interestingly, switching from three carbons to two carbons also change from antagonist 
to agonist.  In order to explore the importance of the potential bi-dentate interaction afforded by 
the guanidine certain modifications were made.  First elimination of the primary amine either 
through removal or alkylation leading to a secondary amine afforded compounds with affinities 
of 1379 nM at NPFF1 and 5110 nM at NPFF2 and 1187 nM at NPFF1 and 4387 nM at 
NPFF2 respectively.  Bulkier substitutions off of the terminal amine did not improve 
affinity.  Likewise isosteric replacement of the imine with a carbonyl group did not improve 
affinity giving 11780 nM at NPFF1and 17580 nM at NPFF2.  In addition changing the primary 
amine to a sulfur group did not improve affinity over the original guanidine structure.  Moreover 
simply giving a compound a permanent charge also gave affinities greater than the limits of the 
assay at both NPFF1 and NPFF2.  In fact the only change to the guanidine structure that was 
tolerated was to create an imide-amine structure, this gave similar affinity to the guanidine 
structure (imine-amine: 330.2 nM at NPFF1 and 1263 nM at NPFF2; guanidine: 477.9 nM at 
NPFF1 and 1677 nM at NPFF2). 
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            Finally previous work in our lab explored the importance of the piperidine nitrogen.  For 
example replacing the nitrogen atom with a double bond gave a compound with affinities in the 
thousand nanomolar range.  Likewise moving the nitrogen atomfrom the four-position to the 
three-position gave affinities of 904 nM at NPFF1 and 1893 nM at NPFF2.  In addition early 
work on substitutions off the nitrogen established that substitutions such as a methyl group or 
ethyl benzyl group caused a poor of affinity for NPFF1 and NPFF2 receptors.  Other substitutions 
did not cause a complete loss of affinity but also did not improve affinity from our lead 
compound.  Therefore choosing substitutions that explored the chemical space surround the 
piperidine nitrogen that had a greater bulk than a methyl group and some degree of planarity as a 
biphenyl substitution lessened affinity was an important step in exploring the structure-activity 
relationship of our lead structure.  
 
            Consequently, aliphatic substitutions such as cyclopropane, cyclopentane, and 
cycloheptane were chosen to explore if an aromatic substitution was necessary.  Likewise, 
choosing pyridine substitutions offered the opportunity to explore the isosteric replacement of a 
carbon with nitrogen in order to compare its affects to the benzyl derivative.  Moreover at the 
start of the project the napthyl derivative was the best lead compound, suggesting a larger planer 
structure was tolerated at the binding site in the receptors.  To further validate this hypothesis 
quinoline and indole derivatives were purposed.  Each of the purposed derivatives would be able 
to be synthesized through a common synthetic intermediate.  This common intermediate could 
then be transformed through established synthetic procedures to final compounds. 
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 Synthesis of tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-
oxa-2,5,7-triazaundecan-6-ylidenecarbamate, the common intermediate, began with 
commercially available 1-benzylpiperidin-4-one under Strecker-like conditions 
47-49
 to afford in 
68% yield 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile (55).  1-benzyl-4-
(phenylamino)piperidine-4-carbonitrile (55) was then subjected to hydrogenation 
50
 using Raney 
Nickel as the catalyst.  Under these hydrogenation conditions the nitrile was selectively reduced 
to a primary amine in 97 % yield while no side reactions such as debenzylation of the piperidine 
nitrogen occurred.  4-(aminomethyl)-1-benzyl-N-phenylpiperidin-4-amine (56) underwent 
peptide coupling procedure
51, 52
 affording in 72% yield tert-butyl (2-(((1-benzyl-4-
(phenylamino)piperidin-4-yl)methyl)amino)-2-oxoethyl)carbamate (57)-- the BOC-group 
protected glycine derivative.  Next BOC-group deprotection
53
 utilizing trifluoroacetic acid 
results in near quantitative yield of the free amine 2-amino-N-((1-benzyl-4-
(phenylamino)piperidin-4-yl)methyl)acetamide (58).  Finally addition of the BOC-protected 
guanidine substitution is completed using a thiol derivative and base to yield tert-butyl 1-(1-
benzyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6-
ylidenecarbamate (59)
54
 in 62% yield (Scheme 1). 
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Scheme 1 General Synthetic Scheme for key intermediate 
 
Reagents and Conditions: a) Aniline, TMSCN, TEA, CH2Cl2; b) Raney Nickel, H2 (gas), 
CH3OH; c) HOBt, EDCI, BOC-Gly-OH, TEA, CH2Cl2; d) TFA, CH2Cl2; e) 1,3-bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, DMF. 
 
 Scheme 2 offers an alternative route to the diversification by introducing the piperidine 
nitrogen substitution prior to addition of the guanidine substitution.  However, this method was 
not utilized in the synthesis of the final compounds. 
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Scheme 2 Alternative synthetic route to diversification
 
Reagents and Conditions: a) Aniline, TMSCN, TEA, CH2Cl2; b) Raney Nickel, H2 (gas), 
CH3OH; c) HOBt, EDCI, BOC-Gly-OH, TEA, CH2Cl2; d) Pd/C, H2 (gas), CH3OH sat NH3; e) 
ROH or RX, potassium carbonate, DMF. 
 
 Scheme 3 shows the general reaction scheme for the synthesis beginning with tert-butyl 
1-(1-benzyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-
triazaundecan-6-ylidenecarbamate (59) proceeding to tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-
(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63) via 
hydrogenation
55, 56
 utilizing palladium on carbon as the catalyst.  Diversification of the structures 
through N-alkylation (64-72), and removal of protecting groups
53
 with trifluoroacetic acid 
afforded final compounds 73-81. 
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Scheme 3 General synthetic scheme for diversification of key intermediate to final 
compounds 
 
Reagents and Conditions: a) Pd/C, H2 (gas), CH3OH sat. NH3; b) ROH or RX, potassium 
carbonate, DMF; c) TFA, CH2Cl2 
 
 Synthesis of N-((1-(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-
guanidinoacetamide (73) was achieved from deprotection of tert-butyl 1-(cyclopropylmethyl-4-
(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6-
ylidenecarbamate (64) (Scheme 4).  tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-
(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63)  underwent N-
alkylation with addition of bromomethylcyclopropane and base (DIPEA) at 80 ºC for 24 hours 
and yielded tert-butyl 1-(cyclopropylmethyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-
dioxo-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (64)
57, 58
 in 33% yield. tert-Butyl 1-
(cyclopropylmethyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-
triazaundecan-6-ylidenecarbamate (64) and TFA were stirred together for 4 hours to give N-((1-
(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (73)
53
 in 
97% yield. 
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Scheme 4 Synthesis of N-((1-(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-
guanidinoacetamide (73) 
 
Reagents and Conditions: a) DIPEA, bromomethylcyclopropane, 80 ºC, ACN, 24 hours; b) TFA, 
DCM 
 
 tert-Butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-
triazaundecan-6-ylidenecarbamate (63), neopentyl bromide, and DIPEA were combined in 
acetonitrile and left to stir at room temperature for 48 hours to yield
59
 tert-butyl 1-(neopentyl-4-
(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6-
ylidenecarbamate (65) at 25% yield.  tert-butyl 1-(neopentyl-4-(phenylamino)piperidin-4-yl)-
10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (65) was then 
deprotected
53
 with trifluoroacetic acid in DCM set to stir for three hours to yield 2-guanidino-N-
((1-neopentyl-4-(phenylamino)piperidin-4-yl)methyl)acetamide (74) at 20% yield (Scheme 5). 
 
Scheme 5 Synthesis of 2-guanidino-N-((1-neopentyl-4-(phenylamino)piperidin-4-
yl)methyl)acetamide (74) 
 
 
Reagents and Conditions: a) neopentyl bromide, DIPEA, r.t., ACN, 48 hours; b) TFA, DCM, 3 
hours. 
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 Synthesis of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(phenylamino)-4-
(2H-1,2,3,4-trazol-5-ylmethyl)cyclohexyl]methyl}carbamoyl)methyl]amino})methyl]carbamate 
(66) was achieved by the reaction of potassium carbonate, chloromethyltetrazole, tert-butyl 
10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6-
ylidenecarbamate (63) and a catalytic amount of potassium iodide in acetonitrile with heating 
(100 ºC)
60
 at 75% yield.  Deprotection
53
 of tert-butyl N-[(1Z)-{[(tert-
butoxy)carbonyl]imino}({[({[1-(phenylamino)-4-(2H-1,2,3,4-trazol-5-
ylmethyl)cyclohexyl]methyl}carbamoyl)methyl]amino})methyl]carbamate (66) with 
trifluoroacetic acid resulted in 30% yield of N-((1-((1H-tetrazol-5-yl)methyl)-4-
(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (75) (Scheme 6). 
Scheme 6 Synthesis of N-((1-((1H-tetrazol-5-yl)methyl)-4-(phenylamino)piperidin-4-
yl)methyl)-2-guanidinoacetamide (75) 
 
Reagents and Conditions: a) chloromethyltetrazole, potassium carbonate, potassium iodide, 
ACN, 100 ºC to r.t., 39 hours; b) TFA, DCM, 4 hours. 
 
 tert-Butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-4-
ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67) was 
synthesized by combining tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-
yl)-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63), 4-bromomethylpyridine, and DIPEA in 
DMF at room temperature and allowing it to stir for 19 hours
61, 62
 at 60% yield.  Deprotection
53
 
34 
 
of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-4-
ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67) 
was afforded by stirring tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-
(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4-
yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67) and TFA for 4 hours yielding 2-
guanidino-N-((4-(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4-yl)methyl)acetamide (76)  at 
90% yield (Scheme 7). 
 
Scheme 7 Synthesis of 2-guanidino-N-((4-(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4-
yl)methyl)acetamide (76) 
 
Reagents and Conditions: a) 4-bromomethylpyridine, DIPEA, r.t., DMF, 19 hours; b) TFA, 
DCM, 4 hours. 
 
 tert-Butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-
triazaundecan-6-ylidenecarbamate (63), 3-bromomethylpyriidine and Hünig’s base were 
combined in DMF and left to stir for 45 hours
63
 resulting in 60% yield of tert-butyl N-[(1Z)-
{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4-
yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (68).  Deprotection
53
 of the resulting 
pale yellow solid (68) with TFA were stirred in DCM for 4 hours resulting in 90% yield of 2-
guanidino-N-((4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4-yl)methyl)acetamide (77) 
(Scheme 8). 
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Scheme 8 Synthesis of 2-guanidino-N-((4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4-
yl)methyl)acetamide (77) 
Reagents and Conditions: a) 3-bromomethylpyridine, DIPEA, r.t., DMF, 45 hours; b) TFA, 
DCM, 4 hours. 
 
N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide 
(78) and N-((1-(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-
guanidinoacetamide (79) both required the modification of the alkylating agent prior to the N-
alkylation step.  For N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-
guanidinoacetamide (78) the alkylating agent was cycloheptane methanol, in order to create a 
better alkylating agent, the alcohol was converted to a mesylate
64
.  This conversion created a 
better leaving group for the N-alkylation step (Scheme 9).  In the case of N-((1-
(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (79) in lieu 
of creating a mesylate, a tosylate of the alcohol (cyclopentane methanol) was made (Scheme 10).  
The change from mesylate to tosylate assisted in visualization of the product on TLC. 
Scheme 9 Alkylating agent cycloheptylmethyl methanesulfonate (89) 
 
Reagents and Conditions: a) methylsufonyl chloride, TEA, 0 ºC, ethyl acetate, 2 hours. 
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Scheme 10 Synthesis of cyclopentylmethyl tosylate (92) 
 
Reagents and Conditions: a) tosyl chloride, TEA, 0 ºC, ethyl acetate, 3.5 hours. 
 
 
Once the alkylating agent was prepared (89 or 92), synthesis of the corresponding N-alkylated 
analog occurred.  2,2-dimethylpropyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-
(cycloheptylmethyl)-4-(phenylamino)piperidin-4-
yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (69) was synthesized
64
 by combing tert-
butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6-
ylidenecarbamate (63), cycloheptylmethyl methanesulfonate (89), along with potassium 
carbonate and potassium iodide in acetonitrile at 70 ºC.   The reaction stirred for 17 hours at 70 
ºC and after cooling to room temperature was stirred for an additional 5 hours.  Deprotection
53
 of 
2,2-dimethylpropyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(cycloheptylmethyl)-4-
(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (69) utilizing 
TFA in DCM afforded N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-
guanidinoacetamide (78) (Scheme 11). 
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Scheme 11 Synthesis of N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-
2-guanidinoacetamide (78) 
 
Reagents and Conditions: a) cycloheptylmethyl methanesulfonate, K2CO3, KI, ACN, 70 ºC to 
r.t., 22 hours; b) TFA, DCM, 5 hours. 
 
 With cyclopentylmethyl 4-methylbenzenesulfonate (92) in hand, addition of tert-butyl 
10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6-
ylidenecarbamate (63), potassium carbonate, and potassium iodide were set to stir in ACN at 70 
ºC
64
.  The reaction stirred at 70 ºC for 24 hours was then left to stir at room temperature for 18 
hours with poor yield of 12% despite monitoring of the reaction via TLC.  tert-butyl N-[(1Z)-
{[(tert-butoxy)carbonyl]imino}({[({[1-(cyclopentylmethyl)-4- 
(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (70) 
 underwent deprotection
53
 with TFA in chloroform resulting in N-((1-(cyclopentylmethyl)-4-
(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (79) in 85% yield (Scheme 12). 
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Scheme 12 Synthesis of N-((1-(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-
2-guanidinoacetamide (79) 
 
 
Reagents and Conditions: a) cyclopentylmethyl tosylate, K2CO3, KI, ACN, 70 ºC to r.t., 22 
hours; 2) TFA, DCM, 4 hours.  
 
Synthesis of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-
(quinolin-8-ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (71) 
began by combining tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-
oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63), 8-bromomethylquinoline, and DIPEA in DMF 
at room temperature
65
.  The reaction stirred for 21 hours with 59% yield of desired product (71).  
Deprotection of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-
(quinolin-8-ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (71) 
using TFA in chloroform resulted in 90% yield of 2-guanidino-N-((4-(phenylamino)-1-(quinolin-
8-ylmethyl)piperidin-4-yl)methyl)acetamide (80) (Scheme 13). 
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Scheme 13 Synthesis of 2-guanidino-N-((4-(phenylamino)-1-(quinolin-8-ylmethyl)piperidin-
4-yl)methyl)acetamide (80) 
Reagents and Conditions: a) 8-bromomethyl quinoline, DIPEA, r.t., DMF, 21 hours; b) TFA 
CHCl3, 4 hours. 
 
 In order to synthesize tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]amino}({[({[1-(1H-
indol-6-ylmethyl)-4-nylamino)piperidin-4-
yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72), (1H-indol-6-yl)methyl 4-
methylbenzenesulfonate (96) need to first be prepared.  Preparation of (1H-indol-6-yl)methyl 4-
methylbenzenesulfonate (96) began first with reduction
66
 of commercially available 1H-indole-6 
carboxylic acid at 91% yield (Scheme 14).  Following the reduction the (1H-indole-6yl) 
methanol (95) was then converted to a tosylate using 4-methylbenzene-1-sulfonyl chloride and 
triethylamine in ethyl acetate resulting in 50% yield of (1H-indol-6-yl)methyl 4-
methylbenzenesulfonate (96) (Scheme 15) 
64
. 
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Scheme 14 Synthesis of (1H-indol-6-yl)methanol (95) 
 
Reagents and Conditions: a) LAH, THF, r.t. to 0 ºC, 25 hours. 
 
Scheme 15 Synthesis of (1H-indol-6-yl)methyl 4-methylbenzenesulfonate (96) 
 
Reagents and Conditions: a) tosyl chloride, TEA, ethyl acetate, 4 hours. 
 
 tert-Butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-
triazaundecan-6-ylidenecarbamate (63), (1H-indol-6-yl)methyl 4-methylbenzenesulfonate (96), 
potassium carbonate, and potassium iodide were combined in ACN and left to stir for 48 hours at 
70 ºC and then allowed to cool to room temperature where the reaction continued to stir for an 
additional 17 hours
64
.  This resulted in 14% yield of tert-butyl N-[(1Z)-{[(tert-
butoxy)carbonyl]amino}({[({[1-(1H-indol-6-ylmethyl)-4-nylamino)piperidin-4-
yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72).   Deprotection
53
 of tert-butyl 
N-[(1Z)-{[(tert-butoxy)carbonyl]amino}({[({[1-(1H-indol-6-ylmethyl)-4-nylamino)piperidin-4-
yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72) using TFA in chloroform  
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resulted in 53% yield of N-((1-((1H-indol-6-yl)methyl)-4-(phenylamino)piperidin-4-yl)methyl)-
2-guanidinoacetamide (81) (Scheme 16).  Final compounds purity and compositions were 
verified through various analytical methods including NMR, HPLC, and MS. 
 
Scheme 16 Synthesis of N-((1-((1H-indol-6-yl)methyl)-4-(phenylamino)piperidin-4-
yl)methyl)-2-guanidinoacetamide (81) 
 
 
Reagents and Conditions: a) K2CO3, KI, 70 ºC to r.t., ACN, 65 hours; b) TFA, CHCl3, 4 hours. 
 
IN VITRO EVALUATION AND RESULTS 
 In order to create the most viable leads, in vitro evaluation was conducted in two stages.  
The first stage consisted of a receptor binding assay.  The receptor binding assay was performed 
by our collaborators at the Institut de Pharmacologie et Biologie Structurale, CNRS in Toulouse, 
France. The affinities of ligands on NPFF1 and NPFF2 receptors were evaluated by competition 
experiments using the selective NPFF1 and NPFF2 radioligands  [
3
H]-NPVF and [
3
H]-EYF, 
respectively, in membranes of CHO cells stably expressing each receptor
67, 68
.  The non-specific 
binding was determined in the presence of 1 µM YVPNLPQRFa (for hNPFF1 receptor) and 1 
µM EYWSLAAPQRFa (for hNPFF2 receptor).   For membrane preparation, CHO cells 
expressing human NPFF receptors were harvested in phosphate buffer saline (PBS), frozen at 
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least for 1 h at -70°C, and then homogenized in 50 mM Tris-HCl, pH 7.4 in a Potter Elvehjem 
tissue grinder. The nuclear pellet was discarded by centrifugation at 1,000 g for 15 min at 4°C, 
and the membrane fraction was collected upon centrifugation of the supernatant at 100,000 g for 
30 min at 4°C. Membranes were aliquoted and stored at –80°C in Tris 50 mM, pH 7.4 and the 
protein concentration was determined by the Lowry method.  Binding of [
3
H]-NPVF and [
3
H]-
EYF was measured by rapid filtration. Membranes (5-15 µg protein) were incubated in 
polypropylene tubes in a final volume of 500 µl containing 50 mM Tris-HCl, pH 7.4, 0.1% 
bovine serum albumin, 60 mM NaCl (for NPFF2 receptors only), the radioligand at 0.5-1 nM  
and compounds to be tested at the desired concentration.  After 1 h incubation at 25°C, samples 
were rapidly filtered on Whatman GF/B filters preincubated in 0.3% polyethylenimine. The 
filters were rinsed three times with 4 ml of ice cold buffer containing 0.1 % bovine serum 
albumin, and the bound radioactivity was counted in a liquid scintillation spectrophotometric 
counter (50 % efficiency, Packard).  [
3
H]-NPVF and [
3
H]-EYF were custom-made by RC 
TRITEC AG (Teufen, Switzerland) by hydrogenation of the unsaturated peptide precursors with 
99% tritium gas.  Tritiated products were purified (> 98%) by HPLC and dissolved in ethanol to 
obtain 1 mCi/ml (37 MBq/ml).  To further test the molecule in a functional assay binding 
affinities must be less than 300 nM.  In the case of the compounds described in this work none 
showed binding affinities less than 300 nM and were therefor not screened in a functional assay.  
Figure 23 describes the binding data for some of the relevant synthesized compounds including 
those described above. 
 The newly synthesized compounds help further elaborate certain trends established in our 
current understanding of the receptor binding space and differences between NPFF1 and NPFF2 
receptors.  For instance, previously synthesized compounds showed that a lack of substitution of 
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the piperidine nitrogen or a simple methyl substitution do not afford strong binding affinities at 
either subtype of receptor.  Moving from a benzyl substitution pattern to a cyclopropyl 
substitution maintains the preference for NPFF1 receptor subtype.  Interestingly increasing the 
cyclic aliphatic substitution from a cyclopropyl to a cyclopentyl or cyclohexyl reverses the 
preference from NPFF1 receptor subtype to NPFF2 receptor subtype.  While in the patent 
literature
30
 increases in aliphatic ring size have improved affinity this was not the case for our 
small molecule.  Using an isosteric replacement of nitrogen for carbon in the benzene ring 
substitution we anticipated creating a novel chemical space with similar affinity to the current 
lead compounds.  Yet when tested binding affinities for these molecules were less than the 
benzyl substituted compound and were not further pursued in the functional assays.  However, 
when comparing the isosteric replacement of nitrogen for carbon in our larger planar 
substitutions (naphthalene to quinoline) the relative affinity for each subtype was reversed.  In 
other words, the naphthalene substituted compound (53, MES305) showed preference for NPFF2 
receptor subtype (129 nM at NPFF2; 538 nM NPFF1); while the quinoline substituted compound 
(80, JVM32) showed preference for NPFF1 receptor subtype (580 nM NPFF1; 1080 nM NPPF2).  
The reasoning behind this reversal may be tied to the 3-D structure of the binding pocket of each 
subtype as well as the relevant amino acids within said binding pocket; since no crystal structure 
of the receptor exists to date this is still theory. 
 Overall, binding data provides a first look at the potential benefits or detriments of 
changes in substitutions of the lead compound.  For the newly synthesized compounds described 
the binding data provides a guide to further lead development and offers potential trends to direct 
selectivity between receptor subtypes. 
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Figure 23 Synthetic Non-Peptide Ligands Binding Data 
 
NT= not tested; data based on displacement of [3H]-NPVF and [3H]-EYF for NPFF1 receptors 
and NPFF2 receptors, respectively.  
45 
 
 
CHAPTER 4 
 
IN VIVO MODELS OF PAIN 
 While in vitro work is a valuable asset to the medicinal chemist, it cannot accurately 
describe what happens in a dynamic living system.   Although arguments can be made on both 
sides for the relevancy, validity, and justification of animal models, to date no viable alternatives 
exist.  Animal models remain relevant because they offer a controlled environment to model 
human behaviors.  Pain requires a wide range of animal models in order to best demonstrate 
clinical relevance.  First a point of clarification, pain is a subjective term and is defined as an 
unpleasant sensory and emotional experience associated with actual or potential tissue damage
69, 
70
.  Therefore a more accurate term to use in regards to animal models is nociception which is 
defined as the neural processes of encoding and processing noxious stimuli
69, 70
.   An ideal 
animal model of nociceptive behavior has the following characteristics
34
:  
 Specific—the stimulus causes the nociceptive response and may be distinguished from 
non-nociceptive causing stimulus 
 Sensitive—the stimulus causes a quantifiable response that correlates to the intensity of 
the response 
 Valid—the model must differentiate between behavioral changes triggered by the 
nociceptive stimulus and those that may be triggered by other stimuli (e.g. a 
pharmacological agent) 
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 Reliable—the model must be consistent in results obtained when animals are retested 
with an identical or equivalent test 
 Reproducible—the results of a test must repeatable within a single laboratory and 
between laboratories. 
Though no animal model matches this ideal completely a variety of models exist that do offer 
relevant options for basic research in nociception and pain. 
 Thermal, electrical, mechanical, or chemical stimuli can be used to test nociception
34
.  
Thermal nociceptive tests include tail-flick, hot plate, paw withdrawal.  The tail-flick test has 
two varieties; the first uses radiant heat to a small area of the tail of the animal, the second uses 
predetermined temperature water and immerses the tail.  Though each of these tests measures the 
time until the animal withdrawals its tail from the stimulus, the area of the tail affected is quite 
different.  In the case of the radiant heat only a very small area of the tail is exposed to the heat 
source and depending on intensity of the heat the reaction time can vary
34
.  For the heated water 
a greater surface area of the tail is exposed to the stimulus and can therefore possibly creating a 
shorter reaction time
34
.  Another thermal nociceptive test is paw withdrawal
34
 or Hargreaves 
method
69, 71
.  In this test heat is applied to a paw instead of the tail; it holds two advantages, first, 
it does not involve the tail—the main temperature-regulating organ of the rodent34; second, use 
of the contralateral paw can be used as a control
69
.  A final thermal nociception test is the hot 
plate test.  For the hot plate test, the animal is placed in a cylindrical container on a heated 
ceramic plate (set temperature such as 52ºC) and the time until either a paw licking or jumping 
response occurs is measured
34
.  Cold variations of tail-flick and hot plate do exist but are use 
much less frequently
34, 69
. 
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 Mechanical tests of nociception usually involve the hind paw of the rodent being tested.  
In one example the hind paw is pinned between a flat surface and a blunt point which can 
increase the pressure applied to the paw in a controlled manner.  The measure of nociception is 
based on the level of pressure prior to the predetermined behavioral reaction (i.e. withdrawal of 
paw or vocalization)
34
.  A variation of this test known as Randall-Selitto method
72
,  involves 
inflaming the paw that is tested and comparing it to a healthy paw.  The method increased 
sensitivity compared to the original test and by using a non-steroidal anti-inflammatory drug 
(NSAID) as well as comparing a healthy and inflamed paw of the same rodent the two major 
pitfalls can be overcome
34
.  The von Frey nociception test involves filaments of a set length and 
varying in diameters set on applicators
69
.  These filaments are calibrated to a certain pressure and 
are applied to the plantar surface of the paw of the rodent and withdrawal of the paw is the 
anticipated response
69
.  Automated apparatus exist to help create a continuous scale of 
stimulation
69
. 
 In addition to mechanical and thermal stimulation certain nociceptive models use 
electrical stimulation.  Electrical stimulation offers a non-specific response that does not have a 
direct link to nociception.  Different levels of electrical stimulation are used and most often the 
measure of threshold is based on flinching/movement or escape, vocalization and biting of 
electrodes
34
.  While electrical stimulation usefulness stems from the variety of behaviors that 
may be measured and its non-invasive nature overall it is no longer popular
34
. 
 Chemical stimuli offer an important variation that differs from thermal, mechanical, or 
electrical stimuli.  Chemical stimulation often most closely resembles clinical pain
34
 due to its 
ability to produce distinct behaviors that are not measured at a threshold but instead are 
quantified by time engaged in the specific behavior.  Chemical stimulation models tonic pain and 
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involve intradermal or intraperitoneal injections
34, 69
.  The two most common examples of 
chemical stimulation are the writhing test and the formalin test.  The writhing test begins with an 
intraperitoneal injection in the mouse or rat.  The algesiogenic agent traditionally used is 
phenylbenzoquinone yet many modifications have been made to the agent injected including 
concentration, temperature, and volume as well as the exact agent used
34
.  Some of the behaviors 
observed are abdominal contractions, twisting of abdominal muscles, and a lessening of motor 
activity
34
.  These behaviors are measured as an occurrence per unit of time
34
.  Whereas the 
writhing test is not very specific in that other non-analgesic agents may alter the observed 
behaviors, it does offer a degree of sensitivity that other tests may not. 
 Chemical, electrical, mechanical, and thermal stimuli offer variety and reproducible 
results for short duration models of pain.  Although chemical stimulation can depict a longer 
duration of pain it still does not offer the same clinical relevance for describing chronic pain.  In 
order to model chronic pain such as neuropathic pain more complex and involved models are 
used.   
 For example drug induced neuropathic pain models attempt to recreate the chronic pain 
that can arise from cancer chemotherapy treatments.  Certain natural product derived 
chemotherapeutic agents are known to cause pain in the peripheral nerves.  Animal model of 
vincristine (a vinca alkaloid from the periwinkle plant) neuropathic pain demonstrates a dose-
dependent mechanical allodynia as well as sensitivity towards changes in temperatures
73, 74
.  In 
addition to vincristine, paclitaxel derived from Pacific yew trees can also cause a state of chronic 
pain with repeated exposure such as chemotherapy treatment.  In the case of paclitaxel, animal 
models again demonstrate similar results to human clinical experiences by producing allodynia 
and thermal hyperalgesia
73, 74
.  The rate and quantity of dosing can affect the severity of the pain 
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produced in the animal model and high versus low dose models each have merits depending on 
which symptoms wish to be studied.  Another chemotherapeutic agent that causes neuropathic 
pain in patients is cisplatin
73, 74
.  This agent interferes with DNA which may be part of the cause 
of the neuropathy
73
.  Cisplatin also causes nephrotoxicity which can complicate the creation of a 
complete animal model due to systemic toxicity occurring prior to the neurotoxicity
74
.  These 
difficulties have been overcome by adjusting the dosage and schedule of dosing in the animal 
models
74
.  
 Animal models of drug-induced neuropathic pain are just one example of chronic pain 
models.  Clinical examples of chronic pain may stem from a preexisting condition or disease; as 
such animal models have been developed to mimic the diseases including the chronic pain that 
may be associated with the disease.  For instance, diabetes can induce peripheral neuropathy, in 
one animal model of this pain the animal is injected with streptozocin (STZ) and alloxan
74
.  
These toxins target β-cells of the pancrease74.  Though this is the most common model for 
studying peripheral diabetic neuropathy it differs in that it can cause severe distress to the animal 
and kill other cells other than the beta cells which may confuse interpretation of the results
73
.  
Genetic models of diabetes are available which to varying degrees can develop peripheral 
diabetic neuropathy
74
.  Post-herpetic neuralgia caused by the herpes-zoster virus affects the 
dorsal root ganglia
73
.   In order to replicate the pain triggered by the latent viral infection animal 
models have attempted to infect the animal with virus
73, 74
.  Within the last decade a non-viral 
model using a potent TRPV1 agonist (resiniferotoxin) which diminishes capsaicin sensitive 
afferents thereby reproducing the mechanical and thermal sensitivities in rats
74, 75
.  Models for 
pain caused by HIV or cancer such as bone cancer exist
73, 74
. 
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 Central pain models are based on spinal cord injuries in humans.  Four main models 
exist, first, weight drop or contusive model, second, photochemical spinal cord injury, third, 
excitotoxic spinal cord injury, and fourth, spinal hemi-section model.  In weight drop or 
contusive model, the spinal cord is exposed and a weight is dropped down a tube to direct the 
drop.  The resulting injury causes a compressed spine as well as physical damage to the cord
73, 74
.  
The damage causes motor and sensory dysfunction and leads to tactile allodynia
73, 74
.  For the 
photochemical spinal cord injury model, a dye (erythrosine B) is injected into the spinal cord.  
The cord is then exposed to argon ion laser which excites the dye causing blood vessel stasis and 
ischemia within the microvasculature of the spinal cord
73, 74
.   In the excitotoxic spinal cord 
injury model, an intraspinal injection of quisqualic acid or other excitatory amino acid causes 
spontaneous pain and mechanical allodynia
73, 74
.  This model demonstrates central mechanisms 
and neuronal substrates responsible for onset and progression of altered sensory states post spinal 
cord injury
73, 74
.  Finally the spinal hemi-section spinal cord injury model mimics Brown-
Sequard Syndrome in humans
74
.  This model involves a longitudinal incision that exposes 
several segments of the spinal cord
74
.  It is advantageous compared to some of the other models 
because the number and types of injured fibers can be controlled
74
.  Moreover, there is a 
separation of the injured and non-injured environments
74
. 
 In addition to central pain models, peripheral nerve injury models also allow for 
exploration of cause and effect of various injuries.  While a variety of models exist, a few are 
more common.  Beginning with the complete sciatic nerve transection or neuroma model where 
a section of the sciatic nerve is removed resulting in formation of a lesion or neuroma (tumor 
composed of nerves growing in all directions)
73, 74
.  This model represents phantom limb pain in 
humans with the exception that in humans generally no nerve lesion exists
73, 74
.  The behaviors 
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observed in the animal model include autotomy or self-attack and mutilation of denervated 
limb
73, 74
.  Chronic constriction injury model starts with exposure of the sciatic nerve then three 
to four loose ligatures are tied around the nerve
74
.  Constriction of the sciatic nerve is associated 
with intraneural edema, focal ischemia, and Wallerian degeneration
74
.  These lead to behavioral 
manifestations of spontaneous pain like licking, limping and mild to moderate autotomy
74
.  The 
chronic constriction model is used in research for spontaneous pain and abnormal sensation
74
.  
The Seltzer model
76
 or partial sciatic nerve injury involves exposure of the sciatic nerve with a 
tight ligation on 1/3 to ½ of common sciatic nerve diameter
74
. 
 Partial sciatic nerve injury mimics the neuropathic pain seen in humans
74
 suffering from 
causalgia
77—a constant usually burning pain that results from injury to a peripheral nerve and is 
often considered a type of complex regional pain syndrome.  This animal model is useful 
because it has a characteristic immediate onset and long-lasting continuation of touch evoked 
allodynia and hyperalgesia
74
.  Another model of causalgia is the spinal nerve ligation.  This 
model differs from chronic constriction injury and partial sciatic nerve injury in that it induces 
more extensive and relevant damage; likewise, spinal nerve ligation has an advantage that 
injured and intact segments are seperate
73
.   In spinal nerve ligation, behavioral changes like 
mechanical and cold allodynia, thermal hyperalgesia develop within one to two days of the 
surgery and continue for ten to sixteen weeks
74
.  
 In the spared nerve injury model the sciatic nerve along with its three terminal branches 
are exposed.  Two of the branches are tightly ligated while the third is left alone
74
.  This model 
differs from those previously described in it allows for comparison of mechanical and thermal 
stimuli of non-injured areas next to the injured area thereby allowing for further elucidation of 
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the affects unharmed nerves have in relation to the injured nerves
74
.  Figure 24 offers a 
visualization of some of the peripheral nerve models
74
. 
 In the end, whether an animal model induces a state of pain through a thermal, 
mechanical, or chemical stimulus is short- or long-tern the validity of the model stems from the 
information generated.  If the model can effectively translate human pain symptoms and 
conditions then it can offer a reasonable option for researchers in the quest for understanding and 
discovery. 
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Figure 24 Peripheral Nerve Models 
 
Various peripheral nerve injury models: 1) spinal nerve ligation; 2) chronic constriction injury 
using four ligatures; 3) ligation of common peroneal nerve; 4) neuroma model (complete sciatic 
nerve transection); 5) partial sciatic nerve ligation; 6) spared nerve injury tibial and sural model; 
7) spared nerve injury peroneal and tibial nerve model.  Reproduced with permission from [80]. 
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CHAPTER 5 
FORMALIN ASSAY: EFFECTS OF CONCENTRATION 
 
 As mentioned an effective animal model of nociception is specific, sensitive, valid, 
reliable, and reproducible
34
.  The formalin assay meets these criteria and offers an opportunity to 
explore the connection between nociception and the neuropeptide FF system in the treatment of 
pain.  Since its isolation from bovine brain in 1985
1
, NPFF has been linked to the opioid system 
and its potential role in treatment of pain.  In more recent works, the neuropeptide FF system has 
been linked to inflammatory and neuropathic pain
2, 78-80
.  Likewise the anatomical distribution of 
NPFF receptors in the brain and spinal cord also suggest that the neuropeptide FF system may be 
involved in control of nociception
6, 8
.  Together these factors suggest further study of selective 
neuropeptide FF ligands in the formalin assay may further define the role the NPFF system plays 
in pain management. 
 Initially describe in 1977 by Dubuisson and Dennis, the formalin assay offers an effective 
model of tonic pain
81
.   An intraplantar injection to the hind paw of formalin, a dilute solution of 
formaldehyde, causes a biphasic pain response
81
.   The two phases can act as a screen for 
analgesics with the early phase responding to centrally acting analgesics while the late phase 
responds to peripheral
82
.  Originally an arbitrary scale was established to score behaviors related 
to the manifestation of pain
81
, later works
82-85
 began to use time engaged in characteristic 
behaviors defined as licking, biting, or favoring of injected paw.  Varying concentrations of 
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formalin have been reported to produce the characteristic two phase response of the formalin 
assay
84
.  The purpose of this work was to determine the lowest concentration that demonstrated 
the biphasic pain response at a given dose of morphine.  The behaviors measured were licking or 
biting, of injected paw with measurement of locomotor activity as a secondary measure.  
 Various concentrations of formalin are reported
82, 84, 86-88
 to produce the characteristic 
biphasic response of the formalin assay, in order to determine which concentration would 
produce the best response at a given morphine dose (5 mg/kg) four concentrations (0.1%, 0.2%, 
1%, 5%) were tested.  A control of saline pretreatment (1mg/kg, i.p.) followed 15 minutes later 
with a 10 µL of saline (intraplantar) was established.  Likewise a second negative control of 
pretreatment with morphine (5 mg/kg, i.p.) followed by 10 µL saline (intraplantar) verified that 
the neither intraplantar nor intraperitoneal injections would affect the outcomes for the formalin 
injections (Figure 25).   
 A formalin concentration of 0.2% did not show significance versus saline at any time 
point throughout the experiment (Figure 26).  0.1% formalin concentration showed significance 
(p< 0.01) at the 15 minute time point compared to saline (Figure 27).  While 1% formalin 
concentration showed significance (p< 0.5) at the 5 minute time point (Figure 28).  Finally 5% 
formalin concentration showed significance (p< 0.01) at the 5 minute and 40 minute time points, 
while at the 55 minute time point significance was less (p< 0.5) and at the 60 minute time point 
significance was greatest (p< 0.001) (Figure 29).  In addition to the representative pain 
behaviors of licking or biting of injected paw, locomotor activity was also monitored.  It was 
found that neither the saline nor formalin intraplantar injection at any concentration significantly 
diminished or increased locomotion relative to saline (Figure 30). 
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Figure 25 Controls for Formalin Assay
  
15 minute pretreatment with 1 mg/kg saline or 5 mg/kg i.p. morphine; 10 µL intraplantar 
injection of saline, * p< 0.5.
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Figure 26 Formalin Concentration of 0.2%
 
15 minute pretreatment with morphine (5 mg/kg, i.p.) followed by 10 µL saline or 0.2% formalin 
intraplantar injection. 
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Figure 27 Formalin Concentration of 0.1%
 
15 minute pretreatment with morphine (5 mg/kg, i.p.) or saline (1 mg/kg, i.p.) then 10 µL saline 
or 0.1% formalin intraplantar injection, * p< 0.5, ** p< 0.01. 
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Figure 28 Formalin Concentration of 1%
 
15 minute pretreatment with saline (1 mg/kg, i.p.) or morphine (5 mg/kg, i.p.) then 10 µL saline 
or 1% formalin intraplantar injection, * p< 0.5. 
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Figure 29 Formalin Concentration of 5% 
 
15 minute pretreatment with saline (1 mg/kg, i.p.) or morphine (5 mg/kg, i.p.) followed by 10 µL 
intraplantar injection of 5% formalin, * p< 0.5, ** p< 0.01, *** p<0.001. 
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Figure 30 Locomotor Activity for Formalin Assay
 
No statistically significant difference between saline and formalin concentrations. 
 
 The data obtained are in agreement with several reports in the literature
81-91
.  For instance 
while 20 or 25 µL is used as the volume for intraplantar injection of formalin in mice
82, 83, 85
 and 
50 µL for rats
81, 88
, 10 µL injection volume has been used in mice in the orofacial version of the 
formalin assay where the injection site is located on the face of the animal as opposed to the 
paw
86, 87, 90
.  In this work, 10 µL formalin injections into the paw still produced the expected 
biphasic response.  Moreover based on work by Bornhof
86
, Rosland
84
 and Sufka
85
 a morphine 
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dose of 5 mg/kg was chosen because it produced statically significant pain relief and still showed 
the desired biphasic response.  Similarly effect of formalin concentration has also been 
explored
84-87
.  Again the present work also demonstrates that though low concentrations of 
formalin (0.1%, 0.2%, 1%) do produce both an early and late phase of manifestations of pain (i.e. 
licking or biting of injected paw), the statistical significance is not as strong compared to 5% 
formalin concentration. 
 Overall the formalin assay provides a tonic model of pain that differs in both duration and 
type of stimulus from the hot plate and tail-flick assays the other traditional methods for testing 
of analgesics.  For the work presented 5% concentration of formalin offers the best opportunity 
to observe the biphasic response with a pretreatment of morphine (5 mg/kg, i.p.).  Like 
previously reported
82-88, 90, 91
 each concentration demonstrated the expected two phases however 
only the 5% concentration showed multiple time points as having statistical significance.  By 
only measuring the time spent engaging in pain behaviors of licking or biting of the injected paw 
numbers are lower (but reliable) than others reported in the literature
82, 84, 85
.  The present work 
confirms what is represented in the literature
81-91
 with the addition of a smaller intraplantar 
injection volume can still produce the desired characteristics of the formalin assay. 
 In terms of NPFF ligands, selectivity and the exact pharmacology of NPFF are still 
pertinent issues that need to be resolved.  NPFF has been demonstrated to cause both anti-
nociceptive as well as pro-nociceptive properties
9
.  Interestingly in models of inflammation such 
as Complete Freud’s Adjuvant model NPFF has an anti-allodynia affect78.  While the formalin 
assay is a less formal model of inflammation, it may prove interesting to see if selective NPFF 
ligands can reduce the late phase of the formalin assay. For instance early work on a selective 
NPFF2 ligand does in fact show a statistically significant decrease in licking/biting in a rat model 
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of the formalin assay
9
.  Likewise, recent work
92
 suggests that the late phase of the formalin assay 
may be spinally modulated therefore intrathecal administration of NPFF or selective NPFF2 
ligands may offer greater insight into these claims.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 For over 25 years research on neuropeptide FF has defined and redefined the role of this 
RF-amide peptide.  Early work focused on defining with which receptors neuropeptide 
interacted
4
 as well as determining which amino acids within the peptide were critical for affinity 
and activity
17
.  Pharmacological studies began to further develop the roll of NPFF from anti-
opioid activity
1
 to temperature regulation
15
 to effects on food intake
13
.  With nearly a decade of 
research already complete the role of NPFF had clear links to pain modulation
12, 78, 93
 and 
development began to move towards creating selective ligands
5, 21, 44
 for the two NPFF receptor 
subtypes (NPFF1 and NPFF2).  While peptide work
27
 continued in the next decade of NPFF 
research, small molecules selective for NPFF1 or NPFF2 receptors began to appear in the patent 
literature
30, 32, 35, 36, 38, 39, 66
.  Often these molecules contained a heterocycle and a guanidine 
moiety.  While some groups focused on creating selective NPFF2 receptor ligands
29, 31
, others 
worked towards NPFF1 selectivity
35, 36
.  Although a diverse range of substitutions from 
aliphatic
30
 to multiple heterocycles
29
 to hydrazines
31
 can offer selective non-peptide ligands no 
clearer SAR than a heterocycle and a guanidine moiety can be drawn. 
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 To begin the 4-anilidopiperdine core as its features aligned well with the C-terminal 
features of endogenous neuropeptide FF.  Moreover this core offered a synthetically viable 
starting point for a systematic exploration of structural changes affecting affinity toward NPFF 
receptors.  Changes to the substitution pattern around the aniline portion of the core structure did 
not create selective ligands; however, it did create ligands with affinity in the low micromolar 
range.  Replacement of the aniline with a naphthalene-1-amine showed weak binding for NPFF2 
and no displacement of radioligand at NPFF1.  Loss of the aniline nitrogen in other modifications 
did not enhance binding affinity but did switch relative selectivity.  Further refinement around 
the core structure lead to similar types of findings such as moving from an arginine linker to a 
glycine linker between the core and the guanidine moiety switched the ligands from antagonists 
to agonists.    Early work on the substitutions off the piperidine nitrogen suggested that small 
substitutions such as methyl did not enhance binding or selectivity but larger substitutions such 
as naphthalene did improve affinity though not selectivity.  
 To better determine the effects of the substitution off the piperidine nitrogen various 
aliphatic and aromatic substitutions were made.  Isosterically replacing one of the benzyl carbons 
to nitrogen creating pyridine analogs did not improve selectivity or affinity to the NPFF receptor 
subtypes.  Similarly changing from naphthalene to a quinoline substitution did not improve 
affinity but did give a ten-fold selectivity for NPFF1 over NPFF2 receptors.  Substituting an 
indole in place of the benzyl gave weak affinity for NPFF2 and did not displace the radioligand at 
NPFF1.  Switching from aromatic substitutions to aliphatic substitutions overall did not improve 
selectivity or affinity.  Bulky aliphatic substitutions such as a cycloheptyl ring did not bind 
within the limits of the assay perhaps because of the lipophilicity of such a molecule.  However, 
smaller aliphatic substitutions such as cyclopentyl ring and cyclopropyl ring did displace 
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radioligand though again with very weak affinity and minimal selectivity.  In the end none of the 
newly synthesized piperidine nitrogen modifications enhance the lead template design. 
 In addition to synthesis, in vivo pharmacological evaluation is a critical component of 
drug discovery and design.  Described in the beginning as an anti-opioid system, the role of 
NPFF has continued to expand through pharmacological evaluation.  In order to best understand 
NPFF and intern the non-peptide small molecules designed to interact with the NPFF system the 
right pharmacological tools are necessary.  When testing for analgesic effects two main assays 
are used—tail-flick and hot plate.  These assays are well established and describe peripherally or 
centrally mediated responses respectively.  Although these assays are useful, both only measure 
acute pain.  In order to determine if more long term pain relief is possible a model of tonic pain 
is beneficial.  The formalin assay offers this model of tonic pain.  It provides a means to 
distinguish if the analgesic effects are centrally or peripherally located based on which of the two 
phases are affected.  Moreover, various established classes of drugs have proven effects on the 
different phases (early or late) of the assay.  This allows for competing experiments to help 
evaluate the effectiveness of the test compound. 
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 In the future modifications of the guanidine moiety may provide the best opportunity for 
a clinically relevant lead compound.  At present most of these types of modifications has not 
improved affinity or selectivity; therefore, it may require a deeper look into formulation and 
potentially linking one active compound to a molecule or compound that can undergo active 
transport.  Likewise similar molecules have been explored for their interactions with calcium 
channels
94
 consequently it is important to be aware of non-NPFF targets and affects these 
compounds may have.  Furthermore advances in the pharmacological role of NPFF allow for 
opportunities to look at its potential in combating inflammation as well as its anti-opioid 
properties.  In the end as the role of NPFF continues to develop and expand the need for selective 
non-peptide small molecules remains a pertinent challenge.
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Chemistry 
 Reagents and starting materials were obtained from commercial suppliers (Sigma-
Aldrich, Milwaukee, WI) and were used without purification. Pre-coated silica gel GF Uniplates 
from Analtech were used for thin-layer chromatography (TLC). Column chromatography was 
performed on silica gel 60 (Sorbent Technologies).  
1
H and 
13
C NMR spectra were obtained on a 
Bruker APX400 at 400 and 100 MHz, respectively.  The mass spectra (MS) were recorded on 
Waters Acquity Ultra Performance LC with ZQ detector in ESI mode. Chemical names were 
generated using ChemDraw Ultra (CambridgeSoft, version 12.0). 
 
1-benzyl-4-(phenylamino)piperidine-4-carbonitrile (55) 
1-benzylpiperidin-4-one (34.3 mmol) was added to glacial acetic acid and stirred for 10 minutes. 
Then aniline (37.75 mmol, 1.1 equivalents) was added drop wise to the mixture and left to stir 
for 25 minutes at 0 ºC.  Then the reaction mixture was brought to room temperature and left to 
stir for 5 minutes.  After 30 minutes trimethylsilyl cyanide (37.75 mmol, 1.1 equiv) was added 
drop wise.  The reaction was left to stir for six hours and then stopped with the addition of 
aqueous sodium hydroxide to approximately pH of 10.  The solution was extracted three times 
with methylene chloride and the organic layers were dried over sodium sulfate.  The organic 
layers were then evaporated to solid.  Purification through re-crystallization with acetonitrile, 
refluxing for three hours then cool to room temperature and stand overnight in freezer, resulted 
in a fine white solid.  Yield: 68%. IR (neat): 3405, 2228, 1601 cm
-1
, 
1
H NMR (400 MHz, 
CDCl3):  7.43-7.19 (m, 7H), 6.94 (d, J= 7.0 Hz, 3H), 3.71 (s, 1H), 3.57 (d, J= 7.1 Hz, 2H), 2.81 
(s, 2H), 2.41 (d, J= 61.5 Hz, 4H), 1.94 (s, 2H).  
13
C NMR (400 MHz, CDCl3):  143.41, 138.08, 
129.33, 129.03, 128.39, 127.28, 120.90, 120.77, 117.79, 62.63, 53.09, 49.33, 36.13, MS (ESI+, 
m/z) 292.8 (M+1), CHN (expected): C: 78.32, H: 7.26, N: 14.42; CHN (found): C: 78.67, H: 
7.21, N: 14.6. 
4-(aminomethyl)-1-benzyl-N-phenylpiperidin-4-amine (56) 
Compound 55 was added to a hydrogenation vessel along with methanol and a stir bar.  The 
reaction mixture was stirred until no solid particulates were visible.  The stir bar was removed 
and a catalytic amount of Raney Nickel was added to the vessel.  The vessel was set in the Parr 
hydrogenator and the pressure was set to 50 psi.  The reaction was monitored via TLC and was 
stopped after 24 hours.  The Raney Nickel was gravity filtered off through a pad of celite and the 
solution was evaporated to a greenish solid.  Purification via column chromatography 
(DCM/Methanol; 2% methanol gradient) has resulted in yellowish oil. Yield 97%.  
1
H NMR 
(400 MHz, Chloroform-d) δ 7.40 – 7.23 (m, 3H), 7.17 (t, J = 7.7 Hz, 1H), 6.75 (t, J = 7.9 Hz, 
2H), 3.52 (s, 1H), 3.42 (s, 1H), 2.89 (s, 1H), 2.63 (d, J = 11.6 Hz, 2H), 2.32 (t, J = 10.6 Hz, 2H), 
1.99 (d, J = 13.2 Hz, 2H), 1.65 (t, J = 10.5 Hz, 2H).  
13
C NMR (101 MHz, CDCl3) δ 145.69, 
138.08, 129.23, 128.25, 127.12, 118.60, 116.93, 77.48, 77.16, 76.85, 63.18, 54.68, 50.23, 49.08, 
33.41. 
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tert-butyl (2-(((1-benzyl-4-(phenylamino)piperidin-4-yl)methyl)amino)-2-
oxoethyl)carbamate (57) 
Compound 56 (1.157 mmol), EDCI (1.1 equiv.) and NMM (.5 equiv.) were set to stir in 5 mL 
DMF.  After 10 minutes, HOBt in NMM (.5 equiv. in 1.6 equiv.) was added.  Over an hour 
BOC-Gly-OH (1 equiv.) in 1 mL DMF was added to the reaction mixture.  The reaction was then 
flushed with argon gas and left to stir under argon for 18 hours at room temperature.  The 
reaction was stopped by pouring it into water then extracted utilizing ethyl acetate (4 times)  The 
organic layers were combined and extracted once with brine and then dried over sodium sulfate 
and evaporated to dryness.  Purification by column chromatography (1% methanol gradient) 
yielded a white solid.  Yield 72%.  
1
H NMR (400 MHz, Chloroform-d) δ 7.35 – 7.23 (m, 3H), 
7.18 (t, J = 7.8 Hz, 2H), 6.79 (dd, J = 31.7, 7.6 Hz, 3H), 6.60 (t, J = 5.0 Hz, 2H), 5.32 (s, 1H), 
3.75 (d, J = 5.8 Hz, 2H), 3.58 – 3.50 (m, 4H), 2.61 (d, J = 11.9 Hz, 3H), 2.36 (t, J = 9.9 Hz, 3H), 
1.90 (d, J = 13.9 Hz, 3H), 1.75 (t, J = 11.8 Hz, 2H), 1.42 (s, 7H).  
13
C NMR (101 MHz, CDCl3) δ 
169.81, 156.07, 145.19, 137.67, 129.32, 129.19, 128.28, 127.23, 119.45, 117.61, 80.13, 62.87, 
54.38, 48.93, 44.45, 33.41, 28.27.  MS (ESI+, m/z) 453.4 (M+1). 
 
2-amino-N-((1-benzyl-4-(phenylamino)piperidin-4-yl)methyl)acetamide (58) 
 
Trifluroacetic acid (11.824 mmol, 16.6 equiv.) was added to Compound 57 (.7123 mmol) in 
DCM (3mL).  The reaction was left to stir for 3.5 hours at room temperature.  The reaction was 
monitored by TLC.  Upon completion of the reaction the solvent was evaporated off.  
Purification via column chromatography (5% methanol saturated with ammonia gradient) elution 
of desired product between 15-20% methanol saturated with ammonia evaporation of solvent 
yielded fluffy white solid. Yield: 99%.  
1
H NMR (400 MHz, Chloroform-d) δ 7.58 (s, 1H), 7.36 
– 7.23 (m, 3H), 7.16 (t, J = 7.7 Hz, 3H), 6.78 (dd, J = 16.9, 7.8 Hz, 5H), 3.55 (d, J = 8.5 Hz, 6H), 
3.36 (s, 4H), 3.29 (s, 7H), 2.67 (d, J = 11.8 Hz, 2H), 2.41 (d, J = 10.0 Hz, 4H), 1.93 (d, J = 13.3 
Hz, 4H), 1.77 (t, J = 10.3 Hz, 6H).  
13
C NMR (101 MHz, CDCl3) δ 172.47, 145.37, 136.94, 
136.39, 129.36, 129.28, 128.36, 127.45, 119.18, 117.45, 62.72, 54.28, 48.84, 45.49, 44.26, 33.15. 
MS (ESI+, m/z) 353.3 (M+1). 
 
tert-butyl 1-(1-benzyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-
triazaundecan-6-ylidenecarbamate (59) 
Compound 58 (2.41 mmol), 1,3,bis (tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (2.89 
mmol, 1.2 equiv.), and TEA (6.03 mmol, 2.5 equiv.) were set to stir in DMF (10 mL) under 
argon atmosphere at room temperature.  Reaction stirred for 70 hours.  The reaction was stopped 
by pouring into water (approximately ten times volume of DMF) and organic layers were 
extracted utilizing ethyl acetate (30 mL, x3).  The organic layers were collected and dried over 
sodium sulfate.  Purification via column chromatography (5% methanol gradient, eluted at 10% 
methanol) yielded pale yellow solid.  Yield 62%.  
1
H NMR (400 MHz, Chloroform-d) δ 11.34 (s, 
1H), 8.82 (s, 2H), 7.95 (s, 1H), 7.27 (s, 5H), 7.21 (s, 3H), 7.12 (t, J = 7.5 Hz, 4H), 6.79 – 6.62 
(m, 7H), 3.97 (d, J = 4.7 Hz, 5H), 3.55 – 3.46 (m, 10H), 2.90 (s, 3H), 2.84 (s, 3H), 2.58 – 2.50 
(m, 7H), 2.35 (t, J = 8.9 Hz, 7H), 1.87 (d, J = 12.2 Hz, 5H), 1.77 – 1.67 (m, 7H), 1.62 – 1.27 (m, 
31H).  
13
C NMR (101 MHz, CDCl3) δ 168.54, 163.04, 162.50, 156.24, 152.72, 145.38, 138.11, 
129.24, 129.09, 128.19, 127.04, 119.17, 117.34, 83.41, 79.47, 76.88, 62.97, 54.51, 49.06, 45.27, 
44.73, 36.43, 33.93, 31.39, 28.25, 28.00.  MS (ESI+, m/z) 581.6 (M+1). 
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tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-
triazaundecan-6-ylidenecarbamate (63) 
Compound 59 (1.67 mmol) was dissolved in methanol (100 mL) in hydrogenation vessel.  After 
Compound 59 was completely dissolved, a catalytic amount of 10% Pd/C was added.  The vessel 
was then evacuated with hydrogen gas and set to 60 psi.  The reaction was monitored via TLC 
throughout the reaction time.  After 14 days the reaction was stopped by filtration of the catalyst 
through a pad of celite.  Purification through column chromatography (11-13% methanol eluent) 
yielded a white solid. Yield 82%.  
1
H NMR (400 MHz, Chloroform-d) δ 11.31 (s, 1H), 8.84 (s, 
1H), 7.14 (t, J = 7.7 Hz, 2H), 6.82 – 6.59 (m, 3H), 3.98 (d, J = 4.1 Hz, 2H), 3.53 (d, J = 5.4 Hz, 
2H), 2.91 (s, 2H), 2.59 – 2.42 (m, 2H), 2.37 – 2.28 (m, 2H), 1.87 (d, J = 12.9 Hz, 2H), 1.70 (d, J 
= 8.5 Hz, 2H), 1.47 (d, J = 5.8 Hz, 18H).  
13
C NMR (101 MHz, CDCl3) δ 168.53, 162.96, 
156.29, 152.73, 145.24, 129.31, 119.47, 117.53, 83.54, 79.70, 77.38, 76.75, 54.96, 45.38, 44.81, 
41.74, 34.47, 28.27, 28.00.  
 
tert-butyl 1-(cyclopropylmethyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-
9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (64) 
Compound 63 (0.244 mmol), bromomethylcyclopropane (0.268 mmol, 1.1 equiv.), and N,N-
diisopropylethylamine (DIPEA; 0.366 mmol, 1.5 equiv.) were set to stir in 3 mL ACN.  The 
reaction was heated to 80 ºC and left to stir for 24 hours.  The reaction was extracted using ethyl 
acetate (6 mL, x 3).  The organic layers were collected and washed once with brine, once with 
distilled water and finally dried over sodium sulfate.   All organic layers were collected and 
evaporated to dryness.  Purification via column chromatography (1% methanol gradient) yielded 
a white solid.  Yield 33%. 
1
H NMR (400 MHz, Chloroform-d) δ 11.30 (s, 1H), 8.86 (t, J = 4.3 
Hz, 1H), 7.13 (t, J = 7.7 Hz, 2H), 6.92 (s, 1H), 6.76 (d, J = 7.9 Hz, 3H), 4.00 (d, J = 4.8 Hz, 2H), 
3.52 (d, J = 5.5 Hz, 2H), 3.08 (s, 2H), 2.90 (s, 2H), 2.59 (d, J = 5.3 Hz, 2H), 2.09 (s, 4H), 1.45 
(d, J = 11.8 Hz, 18H), 1.23 (s, 1H), 1.06 (s, 1H), 0.60 (d, J = 7.6 Hz, 2H), 0.25 (d, J = 4.4 Hz, 
2H). 
13
C NMR (101 MHz, CDCl3) δ 168.67, 162.99, 156.14, 152.69, 145.12, 136.39, 129.35, 
119.79, 117.88, 83.40, 79.46, 62.42, 54.33, 48.56, 44.67, 32.22, 28.30, 28.00, 6.77, 4.44, 0.97. 
 
N-((1-(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide 
(73) 
Compound 64 (0.0585 mmol) was combined with trifluroacetic acid (TFA, 0.0261 mol) in 2 mL 
DCM.  The reaction was set to stir at room temperature for 4 hours after which the solvent was 
evaporated off.  Purification via column chromatography yield white solid.  Yield 93%.  
1
H 
NMR (400 MHz, Methanol-d4) δ 7.30 (d, J = 7.3 Hz, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.89 (d, J = 
7.9 Hz, 1H), 5.03 (s, 10H), 3.95 (s, 1H), 3.53 (d, J = 13.2 Hz, 2H), 3.34 – 3.21 (m, 3H), 3.04 (dd, 
J = 14.3, 7.4 Hz, 2H), 2.31 (d, J = 14.4 Hz, 1H), 2.19 (s, 1H), 2.03 (t, J = 12.6 Hz, 2H), 1.29 (s, 
1H), 1.14 – 1.08 (m, 1H), 0.73 (s, 1H), 0.41 (d, J = 4.5 Hz, 2H).  13C NMR (101 MHz, MeOD) δ 
168.79, 158.01, 144.86, 128.85, 118.83, 116.95, 61.30, 53.46, 45.20, 43.33, 29.85, 5.04, 3.43. 
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tert-butyl 1-(neopentyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-
2,5,7-triazaundecan-6-ylidenecarbamate (65) 
 
Compound 63 (0.3963 mmol), 1-bromo-2, 2-dimethylpropane (0.4359 mmol, 1.1 equiv.), and 
Hünig’s base (0.5945 mmol, 1.5 equiv.) were combined in 5mL ACN and set to stir at room 
temperature.  The reaction was monitored via TLC and determined to be complete after 48 hours.  
The reaction was stopped by pouring into ethyl acetate and extracting the organic layers once 
with sodium bicarbonate, once with brine and once with water.  The organic layers were 
combined and dried over sodium sulfate and evaporated to dryness.  Purification via column 
chromatography yielded a white solid. Yield 25%. 
1
H NMR (400 MHz, Chloroform-d) δ 11.30 
(s, 1H), 9.05 – 8.91 (m, 2H), 7.31 (t, J = 5.9 Hz, 1H), 7.13 (t, J = 7.6 Hz, 2H), 6.80 (d, J = 9.2 
Hz, 3H), 4.06 (s, 2H), 3.53 (d, J = 6.1 Hz, 2H), 3.35 (s, 4H), 2.18 (d, J = 6.5 Hz, 4H), 1.45 (d, J = 
14.9 Hz, 18H).  
13
C NMR (101 MHz, CDCl3) δ 168.79, 162.67, 156.08, 152.64, 144.90, 129.38, 
119.87, 117.93, 83.54, 80.01, 54.26, 40.08, 30.21, 28.30, 28.00. 
 
2-guanidino-N-((1-neopentyl-4-(phenylamino)piperidin-4-yl)methyl)acetamide (74) 
Compound 65 (0.0454 mmol) and TFA (0.0522 mol) in 4 mL DCM were set to stir.  The 
reaction was monitored throughout the reaction time.  After 3 hours the reaction was stopped by 
evaporation of solvent.  Purification via column chromatography yielded a white solid.  Yield 
20%. 
1
H NMR (400 MHz, Methanol-d4) δ 7.37 (t, J = 7.9 Hz, 2H), 7.21 – 7.02 (m, 2H), 4.94 (s, 
13H), 4.38 – 4.27 (m, 0H), 4.23 – 4.09 (m, 0H), 4.02 (s, 2H), 3.80 (td, J = 8.5, 3.8 Hz, 1H), 3.66 
(s, 2H), 3.54 (dd, J = 6.9, 3.4 Hz, 1H), 3.34 (d, J = 15.5 Hz, 2H), 2.45 – 2.13 (m, 1H), 2.04 – 
1.94 (m, 2H), 1.86 (d, J = 8.7 Hz, 3H), 1.82 – 1.72 (m, 2H), 1.60 (s, 0H), 1.29 (s, 1H), 0.96 – 
0.86 (m, 1H).  
13C NMR (101 MHz, MeOD) δ 169.59, 158.01, 129.24, 124.39, 121.34, 59.87, 
43.40, 42.40, 41.86, 37.01, 31.38, 30.81, 19.74. 
 
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(phenylamino)-4-(2H-1,2,3,4-trazol-
5-ylmethyl)cyclohexyl]methyl}carbamoyl)methyl]amino})methyl]carbamate (66) 
Compound 63 (0.400 mmol), potassium iodine (0.0800 mmol, 0.2 equiv.), potassium carbonate 
(1.200 mmol, 3 equiv.) and chloromethyltetrazole (0.440 mmol, 1.1 equiv.) were set to stir in 10 
mL ACN.  The reaction was set to 100 
º
C and left to stir for 19 hours after which the reaction 
was allowed to cool to room temperature and left to stir for 20 hours at room temperature.  
Reaction stopped by evaporation of solvent.  Purification attempts through crystallization and 
TLC were unsuccessful, taken as crude onto next step.  Yield: 75%.  
1
H NMR (400 MHz, 
DMSO-d6) δ 7.84 (s, 0H), 7.02 (s, 6H), 6.77 (s, 6H), 6.55 (s, 3H), 5.74 (s, 1H), 4.10 (s, 7H), 3.88 
(d, J = 13.0 Hz, 2H), 3.79 – 3.72 (m, 4H), 3.68 (s, 1H), 3.62 (s, 0H), 3.46 (s, 3H), 3.35 (s, 16H), 
3.15 (s, 2H), 3.02 (s, 0H), 2.49 (s, 5H), 2.27 – 2.22 (m, 1H), 2.10 – 2.04 (m, 1H), 1.80 (s, 5H), 
1.66 (d, J = 14.7 Hz, 3H), 1.53 (s, 2H), 1.44 (s, 8H), 1.35 (d, J = 6.2 Hz, 7H), 1.22 (s, 1H), 1.10 
(s, 1H). 
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N-((1-((1H-tetrazol-5-yl)methyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-
guanidinoacetamide (75) 
Compound 66 (0.0956 mmol) and TFA (0.0261mol) in 2 mL DCM were set to stir at room 
temperature.  The reaction was left to stir for 4 hours afterwards it was stopped by evaporation of 
solvent.  No further purification attempted. Yield: 30%.   
1H NMR (400 MHz, MEOD) δ 8.59 (s, 
0H), 7.06 (s, 0H), 6.80 (s, 0H), 6.60 (s, 0H), 4.00 (s, 0H), 3.56 (s, 2H), 2.49 (s, 0H), 1.94 (s, 0H), 
1.65 (s, 0H), 1.04 (s, 0H). 
 
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-4-
ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67) 
 
Compound 63 (0.400 mmol), 4-bromomethylpyridine (0.480 mmol, 1.2 equiv.), DIPEA (1.763 
mmol, 4.4 equiv.) were set to stir at room temperature in 5 mL DMF.  The reaction began as a 
blood red color and was left to stir for 19 hours after which it was a brownish color.  The 
reaction was stopped by pouring into ethyl acetate and then water in a separatory funnel.  The 
reaction was extracted using ethyl acetate (10 mL, x5).  The organic layers were combined, 
extracted once with brine and once with water then dried over sodium sulfate and evaporated to 
dryness.  Purification via column chromatography (1% methanol gradient) yielded a pale yellow 
solid.  Yield: 60%.  
1
H NMR (400 MHz, Chloroform-d) δ 11.34 (s, 1H), 8.83 (t, J = 5.5 Hz, 1H), 
8.54 (d, J = 5.0 Hz, 2H), 7.28 (d, J = 4.6 Hz, 2H), 7.16 (ddd, J = 8.5, 5.6, 1.9 Hz, 2H), 6.80 (t, J 
= 7.4 Hz, 1H), 6.77 – 6.68 (m, 2H), 6.52 (dd, J = 8.2, 3.3 Hz, 1H), 3.99 (d, J = 5.2 Hz, 2H), 3.61 
– 3.52 (m, 5H), 2.63 – 2.54 (m, 2H), 2.51 – 2.40 (m, 4H), 1.97 – 1.87 (m, 3H), 1.81 (tt, J = 10.3, 
6.0 Hz, 2H), 1.47 (d, J = 13.2 Hz, 18H).  
13
C NMR (101 MHz, CDCl3) δ 168.57, 163.01, 156.35, 
152.78, 149.83, 145.21, 129.36, 123.87, 119.54, 117.50, 83.58, 79.63, 54.51, 49.22, 44.86, 33.94, 
28.26, 28.01. 
 
2-guanidino-N-((4-(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4-yl)methyl)acetamide 
(76) 
 
Compound 67 (0.0995 mmol) and TFA (0.0404 mol) in 3 mL DCM were set to stir at room 
temperature.  The reaction was left to stir for 4 hours and stopped by evaporation of solvent.  
Purification via column chromatography (1% methanol gradient) yielded a white solid. Yield: 
90%.  
1
H NMR (400 MHz, DMSO-d6) δ 8.86 – 8.79 (m, 8H), 8.00 (d, J = 5.9 Hz, 10H), 7.51 (t, 
J = 5.7 Hz, 2H), 7.11 (t, J = 7.7 Hz, 8H), 6.84 (d, J = 8.0 Hz, 8H), 6.75 (d, J = 7.5 Hz, 4H), 4.46 
(s, 1196H), 3.82 (t, J = 3.0 Hz, 7H), 3.46 (d, J = 5.3 Hz, 8H), 3.34 – 3.23 (m, 16H), 3.14 (p, J = 
1.7 Hz, 5H), 2.14 (d, J = 14.9 Hz, 9H), 1.89 (dt, J = 15.0, 7.6 Hz, 9H), 1.26 – 1.14 (m, 1H), 1.09 
(s, 0H), 0.80 (dt, J = 13.1, 6.8 Hz, 1H). MS (ESI+, m/z) 396 (M+1). 
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tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-3-
ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (68) 
 
Compound 63 (0.396 mmol), 3-bromomethylpyridine (0.436 mmol, 1.1 equiv.), DIPEA (1.742 
mmol, 4.4 equiv.) were set to stir at room temperature in 5 mL DMF.  The reaction began as a 
pale yellow color and was left to stir for 45 hours.  The reaction was monitored via TLC and 
upon completion was extracted using ethyl acetate (10 mL, x4).  The organic layers were 
combined and washed once with sodium bicarbonate, once with sodium hydroxide and once with 
water.  The organic layers were then dried over sodium sulfate and evaporated to dryness.  
Purification via column chromatography (1% methanol gradient) yielded a white solid.  Yield: 
60%.  
1
H NMR (400 MHz, Chloroform-d) δ 11.33 (s, 1H), 8.82 (t, J = 5.3 Hz, 1H), 8.53 – 8.44 
(m, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.24 (dd, J = 7.9, 4.8 Hz, 1H), 7.15 (t, J = 7.7 Hz, 2H), 6.75 
(dd, J = 31.6, 7.6 Hz, 3H), 6.55 (t, J = 5.7 Hz, 1H), 3.98 (d, J = 5.3 Hz, 2H), 3.53 (q, J = 7.5, 6.6 
Hz, 5H), 2.56 (h, J = 7.2, 5.9 Hz, 2H), 2.46 – 2.35 (m, 2H), 1.95 – 1.84 (m, 2H), 1.81 – 1.70 (m, 
2H), 1.47 (d, J = 11.6 Hz, 18H).  
13
C NMR (101 MHz, CDCl3) δ 168.97, 163.42, 156.73, 153.17, 
150.76, 149.09, 145.66, 137.15, 129.74, 127.79, 123.76, 119.84, 117.83, 83.95, 80.01, 64.01, 
60.44, 54.94, 49.47, 45.23, 34.35, 28.66, 28.42.  
 
2-guanidino-N-((4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4-yl)methyl)acetamide 
(77) 
Compound 68 (0.0841 mmol) and TFA (0.0337 mol) in 3 mL DCM were set to stir.  The 
reaction was left to stir for 4 hours and then stopped by evaporation of the solvent.  Purification 
via column chromatography (1% methanol gradient) yielded a white solid.  Yield: 90%.  
1
H 
NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.94 (s, 2H), 8.62 (d, J = 8.1 Hz, 2H), 8.12 – 7.99 
(m, 2H), 7.33 – 7.18 (m, 5H), 6.99 (d, J = 8.2 Hz, 4H), 6.90 (s, 2H), 4.58 (s, 3H), 3.98 (d, J = 9.4 
Hz, 4H), 3.62 (d, J = 11.2 Hz, 4H), 3.45 (h, J = 9.9, 8.3 Hz, 9H), 3.32 (s, 0H), 2.27 (d, J = 15.4 
Hz, 3H), 2.11 (tt, J = 9.4, 5.3 Hz, 5H), 1.41 – 1.27 (m, 1H), 5.21 – 5.16 (m, 1H).  
 
Cycloheptylmethyl methanesulfonate (89) 
 
Cycloheptylmethanol (0.727 mmol), methanesulfonyl chloride (1.090 mmol, 1.5 equiv.), and 
TEA (1.381 mmol, 1.9 equiv.), were combined in 5 mL ethyl acetate.  The reaction was cooled 
to 0 ºC and left to stir for 2 hours.  The reaction was monitored via TLC and upon completion 
was quenched using sodium bicarbonate.  The reaction was extracted using ethyl acetate (10 mL, 
x2) and the organic layers were combined and washed once with brine and once with water.  The 
organic layers were dried over sodium sulfate and evaporated to dryness.  The crude product was 
taken on without further purification.  Yield: 50%.  MS (ESI+, m/z) 207.3 (M+1). 
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2,2-dimethylpropyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(cycloheptylmethyl)-4-
(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (69) 
 
Compound 63 (0.396 mmol), 89 (0.672 mmol, 1.7 equiv.), potassium carbonate (1.028 mmol, 
2.6 equiv.), and potassium iodide (0.0435 mmol, 0.11 equiv.) were combined in 10 mL CAN.  
The reaction was heated to 70 ºC and set to stir for 17 hours.  Then the reaction was allowed to 
reach room temperature and left to stir for 5 hours.  The reaction was monitored via TLC and 
upon completion was extracted using chloroform (10 mL, x3).  The organic layers were 
combined and washed once with brine then dried over sodium sulfate and concentrated to 
dryness.  The crude product was red-orange oil.  Purification via column chromatography (1% 
methanol gradient) yielded a white solid.  Yield 24%.  
1
H NMR (400 MHz, Chloroform-d) δ 
12.10 (t, J = 9.0 Hz, 2H), 8.93 – 8.75 (m, 1H), 8.53 – 8.34 (m, 5H), 7.15 (p, J = 6.5, 6.0 Hz, 7H), 
6.83 – 6.68 (m, 10H), 4.08 – 3.87 (m, 7H), 3.82 (dd, J = 18.3, 9.9 Hz, 2H), 3.54 (p, J = 7.4, 6.2 
Hz, 8H), 3.36 – 3.25 (m, 2H), 1.76 (tt, J = 11.3, 6.3 Hz, 3H), 1.70 – 1.59 (m, 1H), 1.55 – 1.37 
(m, 42H), 1.26 (s, 3H), 1.24 – 1.09 (m, 5H), 0.85 (q, J = 9.4, 8.2 Hz, 2H).  Dept 135: 13C NMR 
(101 MHz, CDCl3) δ 129.36, 119.31, 117.36, 45.03, 40.45, 37.92, 32.72, 28.40, 28.29, 28.04, 
26.20. 
 
N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide 
(78) 
 
Compound 69 (0.0808 mmol) and TFA (0.0337 mol) in 3 mL CHCl3 were set to stir for 5 hours.  
Completion of the reaction was determined by TLC.  Purification via column chromatography 
(1% methanol gradient) yielded a white solid. Yield 30%.  
1
H NMR (400 MHz, Methanol-d4) δ 
7.54 (s, 1H), 7.50 – 7.42 (m, 10H), 7.34 (d, J = 8.1 Hz, 12H), 4.06 (s, 5H), 3.83 – 3.75 (m, 1H), 
3.50 (td, J = 9.6, 4.5 Hz, 2H), 2.35 – 2.30 (m, 1H), 2.24 – 2.18 (m, 0H), 2.09 (s, 7H), 1.98 – 1.89 
(m, 3H), 1.89 – 1.80 (m, 5H), 1.55 (d, J = 11.1 Hz, 1H), 1.37 – 1.25 (m, 15H), 0.99 – 0.86 (m, 
5H), 0.15 – 0.06 (m, 3H).  Dept 135: 13C NMR (101 MHz, MeOD) δ 129.47, 126.85, 123.09, 
122.17, 54.24, 47.88, 43.41, 41.86, 41.23, 37.01, 30.86, 30.23, 19.69.  
13
C NMR (101 MHz, 
MeOD) δ 170.00, 160.66, 129.84, 129.47, 123.11, 123.09, 122.64, 122.17, 61.97, 43.41, 41.87, 
41.22, 37.02, 37.02, 30.23, 19.69. 
 
Cyclopentylmethyl 4-methylbenzenesulfonate (92) 
 
Cyclopentylmethanol (0.740 mmol), 4-methylbenzene-1-sulfonyl chloride (1.109 mmol, 1.5 
equiv.), and TEA (1.405 mmol, 1.9 equiv.) were combined in 5 mL of ethyl acetate and set to stir 
at 0 ºC.  The reaction was left to stir for 3.5 hours.  The reaction was extracted once with sodium 
bicarbonate, once with brine and once with water.  The organic layers were combined, dried over 
sodium sulfate and evaporated to dryness.  The crude product was taken on to the next step 
without further purification. Yield: 50%.  MS (ESI+, m/z) 255.1 (M+1). 
 
  
76 
 
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(cyclopentylmethyl)-4- 
(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (70) 
 
Compound 63 (0.398 mmol), 91 (0.677 mmol, 1.7 equiv.), potassium carbonate (1.036 mmol, 
2.6 equiv.), and potassium iodide (0.0438 mmol, 0.11 equiv.) were set to stir in 15 mL ACN at 
70 ºC.  The reaction was left to stir at 70 ºC for 24 hours.  Then the reaction was allowed to reach 
room temperature and left to stir for 18 hours.  The reaction was monitored via TLC and upon 
completion was extracted using chloroform (20 mL, x3).  The organic layers were combined, 
dried over sodium sulfate and evaporated to dryness.  Purification via column chromatography 
yielded white solid.  Yield 12%.  
1
H NMR (400 MHz, Chloroform-d) δ 7.51 (d, J = 7.7 Hz, 2H), 
7.21 (d, J = 7.8 Hz, 2H), 6.98 (t, J = 7.5 Hz, 2), 6.68 – 6.51 (m, 1H), 3.91 (s, 4H), 3.74 (s, 2H), 
3.63 (d, J = 11.9 Hz, 1H), 3.49 (d, J = 10.6 Hz, 1H), 3.39 – 3.28 (m, 8H), 2.71 – 2.60 (m, 4H), 
2.34 (s, 9H), 2.01 (d, J = 13.8 Hz, 4H), 1.75 (t, J = 12.2 Hz, 1H), 1.67 – 1.53 (m, 4H), 1.36 (s, 
18H).  
13
C NMR (101 MHz, CDCl3) δ 145.26, 143.64, 136.39, 133.06, 129.79, 129.13, 127.60, 
119.19, 117.49, 63.60, 58.96, 44.82, 41.71, 33.25, 29.68, 28.06, 21.53. 
 
N-((1-(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide 
(79) 
 
Compound 70 (0.0372 mmol) and TFA (0.0404 mol) in 3 mL chloroform were set to stir.  After 
monitoring via TLC the reaction was left to stir for 4 hours.  The solvent was evaporated off.  
Purification via column chromatography yielded a white solid.  Yield 85%.  
1
H NMR (400 MHz, 
Methanol-d4) δ 7.61 (t, J = 8.9 Hz, 7H), 7.39 (tq, J = 17.3, 7.3, 5.4 Hz, 14H), 7.24 (d, J = 7.8 Hz, 
5H), 7.11 (dd, J = 6.6, 3.0 Hz, 1H), 4.00 (s, 4H), 3.66 (d, J = 9.2 Hz, 4H), 3.55 – 3.39 (m, 12H), 
3.32 (d, J = 2.4 Hz, 5H), 2.92 (ddd, J = 12.4, 8.9, 3.7 Hz, 5H), 2.59 (tt, J = 13.0, 10.5, 3.9 Hz, 
1H), 2.43 (d, J = 6.0 Hz, 11H), 1.94 (tdd, J = 16.4, 13.6, 6.3 Hz, 12H), 1.79 – 1.64 (m, 5H), 1.29 
(d, J = 3.8 Hz, 7H).  
13C NMR (101 MHz, MeOD) δ 171.83, 159.77, 145.88, 135.08, 131.42, 
131.25, 129.10, 124.87, 65.41, 63.10, 45.17, 45.17, 43.58, 43.06, 31.76, 24.61, 21.93. 
 
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(quinolin-8-
ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (71) 
 
Compound 63 (0.347 mmol), 8-(bromomethyl)quinoline (0.381 mmol, 1.1 equiv.), DIPEA 
(1.526 mmol, 4.4 equiv.) were set to stir in 5 mL DMF at room temperature.  The reaction was 
left to stir for 21 hours and progress was monitored via TLC.  The reaction was extracted using 
ethyl acetate (10 mL, x3); the organic layers were collected and extracted once with brine and 
once with water.  The organic layers were dried over sodium sulfate and evaporated to dryness.  
Purification via column chromatography (1% methanol gradient) yielded a white solid.  Yield 
59%.  
1
H NMR (400 MHz, Chloroform-d) δ 11.33 (s, 1H), 8.90 (dt, J = 4.3, 2.0 Hz, 1H), 8.82 (d, 
J = 5.6 Hz, 1H), 8.14 (dt, J = 8.4, 2.2 Hz, 1H), 7.92 (s, 1H), 7.76 – 7.68 (m, 1H), 7.58 – 7.49 (m, 
1H), 7.39 (ddd, J = 8.3, 4.3, 2.3 Hz, 1H), 7.19 – 7.10 (m, 2H), 6.77 (dt, J = 7.6, 4.0 Hz, 1H), 6.73 
– 6.67 (m, 2H), 6.61 (d, J = 5.8 Hz, 1H), 4.35 (s, 2H), 4.02 – 3.95 (m, 2H), 3.59 – 3.53 (m, 2H), 
2.84 – 2.76 (m, 2H), 2.63 (d, J = 11.2 Hz, 2H), 1.96 (d, J = 13.9 Hz, 2H), 1.88 (s, 1H), 1.46 (dd, 
J = 16.7, 2.3 Hz, 17H).
 13
C NMR (101 MHz, CDCl3) δ 168.55, 163.02, 156.30, 152.75, 149.46, 
146.84, 145.27, 136.35, 129.28, 128.21, 126.40, 120.89, 119.40, 117.50, 83.48, 79.56, 54.34, 
49.31, 44.86, 33.84, 28.26, 28.01. 
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2-guanidino-N-((4-(phenylamino)-1-(quinolin-8-ylmethyl)piperidin-4-yl)methyl)acetamide 
(80) 
 
Compound 71 (0.0675 mmol) and TFA (0.0269 mol) in 2 mL chloroform were set to stir for 4 
hours.  Reaction stopped upon completion via evaporation of solvent.  Purification via column 
chromatography (1% methanol gradient) yielded a white solid.  Yield: 90%.  
1
H NMR (400 
MHz, Methanol-d4) δ 9.04 – 8.98 (m, 2H), 8.50 – 8.42 (m, 2H), 8.11 (d, J = 8.2 Hz, 2H), 7.94 
(d, J = 7.0 Hz, 2H), 7.73 – 7.61 (m, 4H), 7.26 – 7.20 (m, 6H), 6.95 (s, 6H), 4.96 (s, 4H), 4.43 (q, 
J = 7.1 Hz, 2H), 3.96 (s, 5H), 3.66 – 3.40 (m, 12H), 2.33 – 2.24 (m, 4H), 2.06 (s, 0H), 1.57 (s, 
1H), 1.42 – 1.16 (m, 5H).  13C NMR (101 MHz, MeOD) δ 160.92, 151.77, 147.37, 138.87, 
134.41, 131.96, 130.48, 130.12, 128.02, 127.76, 123.48, 118.43, 115.54, 65.66, 44.74, 31.11.  
MS (ESI+, m/z) 446 (M+1). 
 
(1H-indol-6-yl)methanol (95) 
 
1H-indole-6-carboxylic acid (3.116 mmol) was dissolved in THF.  LAH in THF was added 
dropwise with evolution of gas evident.  The reaction was left to stir at room temperature under 
argon gas for 24 hours.  After such time the reaction was cooled to 0 ºC.  10 mL ethyl acetate 
was slowly added then 5 mL methanol at which point evolution of gas was evident.  The reaction 
was left to stir for 1 hour.  The reaction was then filtered through a pad of celite with ethyl 
acetate wash.  The solvent was evaporated off and the residue was dissolved in ethyl acetate and 
extracted twice with brine.  The organic layers were dried over sodium sulfate and evaporated to 
dryness resulting in brown oil.  Yield 91%.  
1
H NMR (400 MHz, Methanol-d4) δ 10.23 (s, 1H), 
7.60 – 7.46 (m, 1H), 7.42 – 7.32 (m, 1H), 7.26 – 7.13 (m, 1H), 7.07 – 6.97 (m, 1H), 6.47 – 6.35 
(m, 1H), 4.71 (d, J = 15.0 Hz, 2H), 4.09 (d, J = 7.1 Hz, 1H).
 13C NMR (101 MHz, MeOD) δ 
137.29, 135.05, 128.26, 125.49, 120.81, 119.65, 110.72, 101.89, 65.93. 
 
(1H-indol-6-yl)methyl 4-methylbenzenesulfonate (96) 
 
4-methylbenzene-1-sulfonyl chloride (2.631 mmol, 2.1 equiv.), 95 (1.257 mmol), and TEA 
(3.587 mmol, 2.9 equiv.) were combined in 50 mL ethyl acetate.  The reaction was set to stir for 
4 hours.  The reaction was quenched with saturated sodium bicarbonate, and then extracted with 
ethyl acetate (x2).  The organic layers were extracted once with brine, and once with water.  The 
organic layers were dried over sodium sulfate and evaporated to dryness.  The crude product was 
taken on to the next step without further purification. Yield: 50%. MS (ESI+, m/z) 302.1 (M+1). 
 
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]amino}({[({[1-(1H-indol-6-ylmethyl)-4-
nylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72) 
 
Compound 63 (0.400 mmol), 96 (0.520 mmol, 1.3 equiv.), potassium carbonate (1.0408 mmol, 
2.6 equiv.), and potassium iodide (0.0440 mmol, 0.11 equiv.) were dissolved in 25 mL ACN.  
The reaction was set to 70 ºC and left to stir for 48 hours.  The reaction was then allowed to 
reach room temperature and left to stir for 17 hours.  The reaction was monitored via TLC.  The 
reaction was quenched with water then extracted with ethyl acetate (x1) and chloroform (x2).  
The organic layers were combined and washed once with brine then dried over sodium sulfate 
and evaporated to dryness.  Purification via column chromatography (1% methanol gradient) 
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yielded white solid. Yield 14%.  
1
H NMR (400 MHz, Chloroform-d) δ 7.61 (d, J = 7.9 Hz, 5H), 
7.42 (q, J = 6.9, 5.9 Hz, 1H), 7.32 (d, J = 7.9 Hz, 5H), 7.08 (t, J = 7.7 Hz, 5H), 6.70 (dd, J = 
21.2, 7.7 Hz, 6H), 4.39 (s, 5H), 3.94 (s, 4H), 3.48 – 3.32 (m, 11H), 2.78 (t, J = 11.3 Hz, 5H), 
2.43 (s, 6H), 2.11 (d, J = 14.0 Hz, 5H), 1.71 (ddd, J = 14.9, 11.3, 4.0 Hz, 5H), 1.49 (s, 19H), 1.27 
(s, 1H).  
13
C NMR (101 MHz, CDCl3) δ 145.45, 144.05, 133.07, 130.00, 129.27, 127.74, 119.22, 
117.54, 59.90, 54.19, 44.32, 41.94, 33.18, 28.15, 21.55. 
 
N-((1-((1H-indol-6-yl)methyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-
guanidinoacetamide (81) 
 
Compound 72 (0.0555mmol) and TFA (0.0337 mol) were combined in 3 mL chloroform.  The 
reaction was left to stir for 2 hours at room temperature.  Purification through column 
chromatography yielded a pale pinkish solid.  Yield 53%.  
1
H NMR (400 MHz, Methanol-d4) δ 
7.63 (d, J = 8.0 Hz, 6H), 7.40 (d, J = 8.0 Hz, 6H), 7.06 (q, J = 7.8 Hz, 6H), 6.66 (dd, J = 14.3, 
7.5 Hz, 9H), 3.92 (s, 6H), 3.69 – 3.55 (m, 1H), 3.46 (s, 6H), 3.45 – 3.37 (m, 6H), 2.77 – 2.65 (m, 
6H), 2.43 (s, 10H), 2.07 (d, J = 13.9 Hz, 6H), 1.72 (ddd, J = 14.6, 11.3, 4.1 Hz, 6H), 1.35 – 1.27 
(m, 4H), 1.18 (t, J = 7.0 Hz, 2H).  
13C NMR (101 MHz, MeOD) δ 171.13, 145.43, 134.61, 
130.97, 130.69, 128.71, 123.31, 65.67, 61.35, 44.76, 43.13, 31.73, 21.51, 13.98. 
 
 
In Vitro Experimental 
 
Membrane Preparation 
 For membrane preparation, CHO cells expressing human NPFF receptors are harvested in 
phosphate buffer saline (PBS), frozen at least for 1 h at -70°C, and then homogenized in 50 mM 
Tris-HCl, pH 7.4 in a Potter Elvehjem tissue grinder. The nuclear pellet is discarded by 
centrifugation at 1,000 g for 15 min at 4°C, and the membrane fraction is collected upon 
centrifugation of the supernatant at 100,000 g for 30 min at 4°C. Membranes are aliquoted and 
stored at –80°C in Tris 50 mM, pH 7.4 and the protein concentration is determined by the Lowry 
method.   
 [
3
H]-NPVF and [
3
H]-EYF are custom-made by RC TRITEC AG (Teufen, Switzerland) 
by hydrogenation of the unsaturated peptide precursors with 99% tritium gas.  Tritiated products 
are purified (> 98%) by HPLC and dissolved in ethanol to obtain 1 mCi/ml (37 MBq/ml). 
 
Binding Assay 
 Binding of [
3
H]-NPVF and [
3
H]-EYF is measured by rapid filtration. Membranes (5-15 
µg protein) are incubated in polypropylene tubes in a final volume of 500 µl containing 50 mM 
Tris-HCl, pH 7.4, 0.1% bovine serum albumin, 60 mM NaCl (for NPFF2 receptors only), the 
radioligand at 0.5-1 nM  and compounds to be tested at the desired concentration.  After 1 h 
incubation at 25°C, samples are rapidly filtered on Whatman GF/B filters preincubated in 0.3% 
polyethylenimine. The filters are rinsed three times with 4 ml of ice cold buffer containing 0.1 % 
bovine serum albumin, and the bound radioactivity is counted in a liquid scintillation 
spectrophotometric counter (50 % efficiency, Packard). 
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In Vivo Experimental 
 
Formalin Assay 
 Animals:  Male Swiss Webster mice (20-30 g) from Harlan Laboratories (Harlan, IN, 
USA) were used for the experiments.  The mice were housed in groups of five with a 12 h 
light/12 h dark cycle. Food and water were provided ad libitum. All mice were randomly 
selected for each treatment group.  Procedures involving animals were performed according to 
the guidelines approved by the Institutional Animal Care and Use Committee (IACUC). 
 
 Drugs and Route of Administration:  Morphine (Sigma-Aldrich, Milwaukee, WI) was 
dissolved in saline (0.9% NaCl) and prepared the day of the experiment.  10% Formalin (Sigma 
Diagnostics Accustain: 10% formalin solution in neutral buffered AFIP; Sigma-Aldrich, 
Milwaukee, WI) was diluted using saline to the appropriate concentration at the prior to the 
beginning of the experiment.  Pretreatment of morphine (i.p.) or saline (i.p) occurred 15 minutes 
prior to formalin injection (10 µL, intraplantar). 
 
 Testing Procedures:  At least one hour prior to testing animals were acclimated to the 
testing environment.  Animals were weighed day of test and acclimated to individual testing 
chambers (16 X 16 X 16 Plexiglas chamber; San Diego Instruments, San Diego, CA) for 30 
minutes.  15 minutes into acclimation to the chamber mice were pretreated with saline (1 mg/kg, 
i.p.) or morphine (5 mg/kg, i.p.). 
At the end of the 30 minute acclimation the animal was dosed intraplantar with 10 µL of 
formalin (0.1, 0.2, 1, or 5%).  The mouse was returned to the chamber where locomotor activity 
was measured and observation of licking or biting of injected paw (established manifestations of 
pain) as a function of time engaged in behavior.  The time of the behavior was measured in five 
minute increments for a total of one hour post formalin injection.  Locomotor activity was 
automatically monitored for 60 min. Total activity was expressed as the total number of 
interruptions of 16 cell photo-beam chambers. 
 
 Statistical Analysis:  All values are expressed as Mean ± SEM with n= 10 animals/group.  
All data were analyzed using one way ANOVA followed by Dunnett's post hoc test to determine 
significant difference from saline control at * p < 0.05, ** p< 0.01, and *** p< 0.001. 
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Murra
y 
Pharmacolo
gy 
7330 dmurray@olemiss.
edu 
      Will assist in 
conducting 
and/or 
supervising 
experiments 
as 
necessary. 
Dr. Murray has 
14 years 
experience 
working with 
rodents. 
Developed and 
perfected 
Millar 
catheterization 
procedure, trai
ned in basic 
animal 
handling, 
 Yes   
 No 
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blood, and 
tissue 
collection, 
arterial and 
venous 
catheterization, 
and general 
rodent survival 
surgery at East 
Carolina 
University 
SOM, Auburn 
University 
CVM, 
University of 
South Carolina 
SOM, and the 
University of 
Mississippi. 
Lisa 
Wilso
n 
Pharmacolo
gy 
7330 llwilso1@olemiss.e
du 
      Lisa will 
conduct 
behavioral 
experiments
, inject 
animals, 
draw blood, 
and dissect 
tissue. 
Dr. El-Alfy has 
trained Lisa.  
She has six 
years 
experience 
conducting in 
vivo animal 
experiments. 
 Yes   
 No 
Jessica 
Mank
us 
Medicinal 
Chemistry 
1663 jvmankus@olemiss.
edu 
      Jessica will 
conduct 
behavioral 
experiments
, inject 
animals, 
draw blood 
and dissect 
tissue. 
Lisa Wilson 
trained Jessica.  
She has one-
year 
experience 
conducting 
behavioral 
experiments. 
 Yes   
 No 
*Surgery requires 1) training and 2) technique performance approval by Dr. Fyke. Submit ‘Proficiency Criteria 
for Research Animal Surgery’ form to Dr. Fyke, B104 NCNPR. 
 
10. Personnel Responsible for Animal Care:    N/A Explain:        
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Name 
 
Phone 
 
Email 
Animal Care [Required: check personnel 
responsible for each] 
Daily Weekend Holiday Emergency 
David 
Murray 
7330 dmurray@olemiss.edu     
Lisa Wilson 7330 llwilso1@olemiss.edu     
Jessica 
Mankus 
1663 jvmankus@olemiss.edu     
Dr. Harry 
Fyke 
915-
5324 
hfyke@olemiss.edu     
 
11. Location/s where Animals Will Be Housed or Procedures will be Performed [check with Animal 
Facility Supervisor about available space and indicate whether animals will be housed for more than 12 
continuous hours for each area]: 
  N/A Explain:        
Building(s)/Room(s) Number: TCRC B070, TCRC B064, TCRC B050, TCRC B049, TCRC B039, TCRC 042, TCRC 040   
>12 hours  Yes    No             Building(s)/Room(s) Number:         >12 hours   Yes    No  
Building(s)/Room(s) Number:         >12 hours  Yes    No             Other Participating Institution:       
B. Overview and Rationale of Study 
 
It is generally not the responsibility or intent of the IACUC to review protocols for scientific merit. 
The following information is required to assist the committee in evaluating the relevance of the 
animal model and procedures to be used. 
 
1. Briefly describe the general experimental design and procedures [This should be no more than 
ONE PAGE and written at HIGH SCHOOL LEVEL or for non-scientists. DO NOT USE JARGON.  
DEFINE ABBREVIATIONS and ACRONYMS. This description should allow readers to understand 
what happens to an animal from its entry into the experiment to the endpoint of the study.  The 
details of specific animal procedures, such as injection sites, surgery, and anesthetics are not 
required here.]: The formalin test affords a model of chronic pain.  While analgesic effects of compounds can 
be monitored through transient pain assays such as hot plate and tail-flick, neither offers a measure of chronic 
pain relief.  As chronic pain has long-term costs and strong clinical relevance an authentic animal model is a 
necessary asset.  Initially the formalin test was done with cats and rats, however, recent adaptations of the test 
allow for use of cost-effective mice as the model animal.   Twenty-four hours prior to testing mice are 
acclimated in the locomotor chambers for one hour.  On test day mice are acclimated to the room for one hour 
and to the locomotor chamber for thirty minutes prior to the first injection.  The initial injection of saline or 
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other vehicle, morphine, or unknown compound will be given systemically (intraperitoneal injection) then ten to 
fifteen minutes later (depending on compound) formalin (at varying percentages e.g. 0.1%, 1%, 5%) will be 
injected to the dorsal left hind paw.  After the formalin injection the mouse will be observed for behaviors such 
as licking or biting of injected paw.  These behaviors will be measured for set time periods and recorded in time 
mouse is performing behavior.   The total time the mouse is involved in the experiment is expected to be one 
and one-half hours.  Paw biting or licking are considered manifestations of pain for the purpose of this test.  
Locomotor activity may also be collected as a secondary measure of pain.  We will be using a modified version of 
SOP entitled Rodent Formalin Test provided by Dr. Ken Sufka.  We will be verifying and adjusting the formalin 
concentration to fit our specific needs--mainly a clear biphasic response with the lowest possible formalin 
concentration. 
 
2. Briefly state the rationale/purpose and significance of the project [This should be no more than 
ONE PAGE and written at HIGH SCHOOL LEVEL and for non-scientists. DO NOT USE JARGON. 
DEFINE ABBREVIATIONS and ACRONYMS.]: Certain assays such as hot plate and tail-flick measure 
transient pain.  However, these assays are unable to evaluate chronic pain.  The formalin test offers an 
opportunity to measure the effectiveness of potential analgesic agents.  The formalin test provides a clinically 
relevant scenario of chronic pain.  Since current pain treatments of pain especially chronic pain are ineffective, 
have low patient compliance, or have adverse outcomes such as high addiction potential new analgesic agents 
are needed to fill this void.  The formalin test allows for testing of analgesic agents in a chronic pain 
environment. 
 
3. Duplication of Research [enter information in table below]: 
Database 
Used 
Publication Years 
Covered 
Key Words Date of 
Search 
Search Results 
From To 
ALTWEB 1980 2011 Alternative 
to formalin 
assay; 
Alternative 
to chronic 
pain model 
5/7/2012  No duplication 
 
 Duplication is necessary 
because:    
           
SciFinder 
Scholar 
1987 2012 Alternative 
to: formalin 
test, formalin 
assay, 
chronic pain 
model  
5/7/2012 
PubMed 1979 2012 Alternative 
to: chronic 
5/7/2012 
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pain model, 
formalin 
assay; 
formalin 
assay; 
chronic pain 
and formalin 
 
4. Animal Model/s:  
*No. of 
Animals 
for 3 yr 
period 
Genus/Species Strain, Stock 
or Breed 
Age and/or 
Size 
Sex Daily Census** 
Average High 
1600 Mouse Swiss Webster 25-40 grams Male 160 280 
* If breeding protocol, put number you are requesting to maintain at any given time. 
* If field study, give your best approximation. 
**During the times animals will be housed, list the average and estimated high # of animals to be housed on 
any given day 
 
5. Provide rationale for choice of animal model/s: Male Swiss Webster mice are commonly used for the 
formalin test where mouse is the species of choice. 
 
6. Justify Animal Numbers: Justification for animal numbers should be thoroughly supported by 
current resources. Information collected from (your and/or previous) research, during 
conferences, from journal articles, and through database searches can help provide statistical 
justifications and sound rationale for the number of animals used: Number of Swiss Webster mice 
needed to evaluate natural product or synthetic compounds for analgesic effects: 
 number of compounds to be tested = 20 / year (2 & 3) 
 number of doses per compound = 4 (+3 standards per compound tested) 
 number of tests per compound = 1 
 number of mice per dose =  10 
 number of mice per year (2 & 3) = 20* 7* 1* 10 = 1,400 mice 
 number of compounds to be tested = 2 (year 1) 
 number of doses per compound = 8 
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 number of tests per compound = 1 
 number of mice per dose = 10 
 number of mice per year (year 1) = 2* 8* 1* 10 = 160 mice 
 
G*Power Analysis suggests a sample size of 13 for one-tail t-test and 16 for a two-tail t-test; therefore, in order 
to have some overlap we will utilize a sample size of 15.  While for the first year we only expect to see a 
decrease in number of licks (how we intend to measure pain perceived), during the second and third years when 
more unknown compounds are tested it may create a hypersensitive response (an increase in number of licks).  
Thus utilizing a sample size of 15 will be able to cover an increase or decrease in pain perceived. 
 
From G*Power (v. 3.1.3):  
t tests - Correlation: Point biserial model 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size |ρ| = 0.7071068 
 α err prob = 0.05 
 Power (1-β err prob) = 0.95 
Output: Noncentrality parameter δ = 4.0000002 
 Critical t = 2.1447867 
 Df = 14 
 Total sample size = 16 
 Actual power = 0.9602208 
 
t tests - Correlation: Point biserial model 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = One 
 Effect size |ρ| = 0.7071068 
 α err prob = 0.05 
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 Power (1-β err prob) = 0.95 
Output: Noncentrality parameter δ = 3.6055515 
 Critical t = 1.7958848 
 Df = 11 
 Total sample size = 13 
 Actual power = 0.9579145 
 
References for G*Power: 
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses using G*Power 3.1: Tests for correlation 
and regression analyses. Behavior Research Methods, 41, 1149-1160.   
 
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the 
social, behavioral, and biomedical sciences. Behavior Research Methods, 39, 175-191. 
 
7. Name of animal supplier or field location: Harlan  
 
8. Animal Type [REQUIRED: Animals will be quarantined upon arrival. Submit animal health status 
report.]: 
 
  In-house transfer [approved form on file]    Bred in-house    Purpose bred 
 
  Wild caught – [complete Appendix III]   Captive bred    From other institution/s [provide 
name]:       
 
9. Is anything other than routine care and equipment required?   Yes – complete checklist   
No 
 
  Solid bottom cages     Laminar flow room      Unique light      Filter tops      
Special diet 
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 Autoclave feed, bedding and cages  Individual housing      Treated water         
 
 Wire bottom cages: Justify:        
 
 Clarify if necessary and/or list other requirements:       
 
10. Describe the cleaning procedures and schedule for animal enclosures not in the vivarium, 
including person responsible for their maintenance. Provide justification if cleaning intervals 
exceed 2 weeks.           N/A:  Vivarium Housing    N/A Explain:        
 
11. Will animals be physically restrained longer than one hour in a conscious state?   
  Yes – complete table & justify  No – proceed to #13 
 
Species Purpose Type of Restraint Frequency Duration 
     
     
Justify duration of restraint:       
 
 
12. How will animals be monitored while they are restrained? [Attach form for monitoring 
physically restrained animals]:       
 
13. Have any of these animals been previously used in an experimental procedure or another 
protocol?  
  Yes – list species and explanation below  No 
 
Species Explanation 
            
            
 143 
 
 
14. Will you be administering a substance?   Yes – complete table below  No 
Species Substance 
Administered 
Dose(s)* Route(s) of 
Administration* 
Frequency Volume Agents 
unknown/not 
previously 
tested in vivo 
Mice Saline (vechile) 1 mg/kg i.p., p.o. 1X 20 L       
Mice 1 cremphor: 1 
ethanol: 18 
saline (vechile) 
1 mg/kg i.p, p.o. 1X 20  L       
Mice Morphine 2-
20mg/kg 
i.p., p.o. 1X 20 L  
Mice Delta-9 THC 0.1-40 
mg/kg 
i.p. 1X 20 L  
Mice Formalin 0.1 -5 % s.c. 1X 20 L  
Mice Natural 
products, with 
potential 
analgesic 
profile 
0.1-30 
mg/kg 
i.p., p.o. 1X 20 L X 
Mice Synthetic 
potential 
analgesic 
agents 
0.1-30 
mg/kg 
i.p., p.o. 1X 20 L X 
      *List all likely doses and routes that may be used 
 
15. Will food and water be provided ad libitum?  
  Yes    No:  list species, explanation, and a description of health and well-being 
assessment methods 
 
Species Explanation Description of assessment 
methods 
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16. Is it likely animals in this protocol will experience pain or distress?  
  No – proceed to #18  Yes – explain and list methods to minimize pain and 
distress: The formalin test is a measure of chronic pain therefore minimization of pain will not be possible 
during the time of testing.  However discomfort caused by the formalin is limited and duration after one hour is 
lessened.  Distress to the mouse will be reduced by acclimation of the mouse to the testing apparatus as well as 
minimal sensory stimulation (e.g. constant room temperature, minimal noise, etc.) outside what is caused by 
the assay.  
 
17. Justify unrelieved severe or chronic pain and distress: In order to discover if the compound being 
tested relieves chronic pain, pain cannot be relieved during the testing period.  Initial tests during year one will 
help to determine the optimal and minimum formalin concentration that elicits a clear biphasic pain response, 
as is characteristic of the formalin test.  Once this concentration is determined all future tests will only use one 
concentration of formalin and there for will provide the least possible stressful environment while still creating 
a valid model of chronic pain. 
 
18. REQUIRED: Conduct literature search for alternatives [ways to reduce numbers of animals 
used, replace animal model, or methods to refine the study to lessen or eliminate pain or 
distress]: 
◦ Date search conducted: 5/7/2012    
◦ Publication years covered: 1979 to 2012 
◦ Keywords/search strategy used [List keywords used to conduct your search using 
terminology from your responses to the above, e.g., alternative, in vitro, in vivo, ex-
vivo, assay, technique, cell culture, cultured cells, tissue culture, simulation, animal 
testing alternative, non-animal model, etc.]: alternative to chronic pain model, alternative to 
formalin assay, chronic pain and formalin, formalin assay, alternative to formalin test. 
 
19. Databases searched/sources consulted for alternatives: 
 
This site must be included in the search:  ALTWEB [http://altweb.jhsph.edu]  
 
Also choose from one or more of the following: 
ASFA     AWIC     AGRICOLA     BIOSIS     CAB     Current Contents     
EMBASE     FEDRIP 
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Google Scholar  Life Sciences    MEDLINE (PubMed)    NTIS    Pascal    
PsycINFO    TOXLINE 
 
SciSearch / Web of Science      Other specialized databases and web resources (specify): 
SciFinder Scholar 
 
20. List any potential alternatives of which you are aware [e.g., alternate models, modified 
techniques, housing modifications, modified restraint, in vitro methods, computer simulations, 
etc.]: No clear alternatives exist for this assay.  Other chronic pain models involve spinal surgical procedures.     
 
21. Did you find any ways to reduce animal numbers? Initial work done in year one to determine the 
minimum optimal formalin concentration will help to reduce animal numbers in the subsequent years.  Likewise 
test compounds can be verified as having analgesic properties (through hot plate and tail-flick assays) prior to 
testing in the formalin assay.  This can limit the number of animals tested. 
 
22. Did you find any methods that minimize pain or distress? By initially testing and verifying the 
concentration of formalin that produces a clear bi-phasic model we will be refining the assay as to minimize pain 
and distress for the animals. 
 
23. Can you replace your animal model with a non-animal model or less sentient species?  
      Why or why not? At this time no in vitro or non-animal models exist as viable alternatives to behavioral 
pain models such as the formalin assay. In order for a pertinent assessment of chronic pain, a living model that 
has sensory input from the extremities to brain and measurable reactive behavior must be used and at this 
point cannot be created outside an animal model. 
 
24. Will you be using non-pharmaceutical grade drugs?   No  Yes – List each drug, its 
intended use, and provide justification [contact Attending Veterinarian (x5324) for ordering 
information]:  The natural products to be tested in the assay may not be pharmaceutical grade due to the 
limited quantities extracted from the source such as plant or marine sponge. 
 
25. Biological Fluids Collection: 
A.  Will biological fluids be collected? [e.g., blood, lymph, bile, cerebrospinal fluid, urine, 
etc.] 
   Yes – complete table below  No – proceed to #26 
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Species Fluid Volume Collection 
frequency 
Collection 
site 
Anesthetic Dose 
                                          
                                          
 
B. If fluids are collected, will animals survive the fluid collection procedure?    Yes    
No   N/A 
 
26. Disposition of Animals (REMINDER: Multiple surgeries require justification.):  
       Will animals be euthanized? 
 Yes – Describe method(s)* by species to be used, including dose and route (if 
applicable): Mice will be euthanized by CO2 asphyxiation. Because CO2 asphyxiation is utilized as the primary 
method for euthanasia, a secondary method such as cervical dislocation will be used to ensure death. 
 
*If CO2, a secondary method of euthanasia to ensure death MUST be used and described above.   
 
 No: 
  Transferred to breeding protocol # _________   
  Transferred to another research protocol # _________     
 Other:       
 
27. Disposal of animals that die while on study:   Freeze    Refrigerate   Do not save   
Other:       
 
28. Humane Endpoints - Ideally, humane endpoints (predictive signs, indicators of an irreversible 
deteriorating condition) should be established prior to beginning animal work.  Realizing the difficulty in 
predicting these for studies which involve compounds with unknown adverse effects, PIs should try to 
develop humane endpoints if severe pain, severe distress, or death is observed. Guidelines should be in 
place to euthanize animals when humane endpoints are reached, when the study objectives have been 
realized, if it becomes clear that they cannot be realized, or whenever the degree of suffering is not 
required or justified by the protocol. 
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A. Explain how animals with severe responses will be handled. All animals will be frequently 
monitored for any signs of severe distress.  The assay focuses on compounds that could be potential 
medications.  Therefore documenting any severe side effects is an essential part of the testing.  
Consequently all animals will go through the whole test session (animal monitoring criteria are 
attached). 
 
B. List signs of pain and distress severe enough to indicate the need for euthanization. Any 
animal showing unusual distress or pain (outside of the parameters of the experiment) such as extreme 
loss of body weight, unusual vocalization when handled, poor grooming or gasping will be euthanized. 
 
C. State the method of euthanasia if different from 25 above.         N/A: Same as 
above 
 
29. Is death, not resulting from euthanasia of any animal subject, an endpoint in any of the studies 
in your project?  No       Yes – provide scientific justification:       
 
30. CHECKLIST:  
      A. Experimental Disease Induction: Will animals be inoculated for experimental purposes? 
   No    Yes – complete Appendix I 
      B. Tumor Induction: Will animals be inoculated with tumor cells? 
   No    Yes – complete Appendix II 
      C. Wild Caught Animals: Will wild caught animals be obtained for this study? 
   No    Yes – complete Appendix III 
      D. Radioisotopes, Toxic Chemicals, or Biological Hazards: Will personnel be exposed to 
radioisotopes,  
          carcinogens, or infectious agents? 
   No    Yes – complete Appendix IV 
      E. Surgical Procedures: Will survival or non-survival surgical procedures be performed? 
   No    Yes – complete Appendix V 
      F. Novel Compounds: Will any new or unknown drugs, compounds, or biological extracts be 
used in this  
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          protocol? 
   No    Yes – complete Appendix VII 
 
C. Investigator Assurance 
 
 or  N/A This application does not diverge from methods/procedures in the full grant 
application (if project  
is funded). 
 
  The information provided in this protocol form accurately reflects the intended use 
of animals for  
this research or teaching activity.  
 
 or  N/A I have consulted with the Attending Veterinarian regarding any experiments that 
are classified in  
pain and distress categories C or D. 
 
  Any changes in procedures will not be undertaken without prior notification and 
approval of the  
Institutional Animal Care and Use Committee. 
 
  The activities described in this study do not unnecessarily duplicate previous 
experiments. 
 
  Prior to participation in the protocol, all persons listed/involved in the use of 
animals on this  
protocol:  
 
◦ Have been informed of the experimental objectives and methods. 
◦ Have received/will receive training in the execution of animal-related 
procedures he/she will perform and will participate in any educational or 
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training programs deemed appropriate or necessary by the IACUC, including 
the mandatory training for research animal surgery. 
◦ Have met/will meet the requirements of The University of Mississippi 
Occupational Health Program. 
 
  I agree to use appropriate anesthesia and/or analgesia to relieve pain/distress 
whenever use of  
these agents will not jeopardize the scientific validity of the data. 
 
  I have read the Guidance on Humane Endpoints and agree to follow it to minimize 
pain, distress or  
illness in laboratory animals. 
 
  I will take appropriate steps to avoid exposure of project personnel to hazardous 
agents in the  
study. 
 
  If the IACUC approves my application, I agree: 
 
◦ To execute this work as described. 
◦ To comply with the guidelines set forth by the IACUC and The University of 
Mississippi’s Department of Health and Safety. 
◦ To be responsible for the supervision and work of my staff. 
 
  I agree to comply with the requirements of the following: 
 
◦ Public Health Service Policy on Humane Care and Use of Laboratory Animals. 
◦ Provisions of the USDA Animal Welfare Act and Regulations. 
◦ UM’s policies governing the use of animals in research, testing, or teaching. 
◦ The Guide for the Care and Use of Laboratory Animals.  
 
State the reason/s if you cannot agree to any of these statements:       
SIGNATURES 
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Department 
 
 
 
 
_______________________________________________ 
 ______________________________________ 
Principal Investigator / Project Director    Date 
 
 
 
 
_______________________________________________ 
 ______________________________________ 
Department Chair       Date 
 
 
 
IACUC Approval 
 
 
 
 
_______________________________________________ 
 ______________________________________ 
IACUC Chair        Date  
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_______________________________________________ 
 ______________________________________ 
Attending Veterinarian      Date  
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STANDARD OPERATING PROCEDURES 
The University of Mississippi Institutional Animal Care and Use Committee 
 
OFFICE USE 
ONLY 
SOP No.        Date Submitted:          Full Committee 
Review Date:         
Approval Date:         
Yr. 2 Review:         Yr. 3 Review:          
INSTRUCTIONS:  Submit one completed form electronically askiacuc@olemiss.edu AND an 
electronic version of the signed copy (faxed to 915-7577)  
 
Title:  Rodent Formalin Test    Author/s:  
Dr. Ken Sufka     
Purpose and Scope:  This SOP describes the materials and procedure used in 
testing inflammatory nociception in rodents    
Materials and Equipment Needed (if appropriate):  Syringe, cloth towel & 
Plexiglas observation chambers      
Required or Specialized Personnel Training on Procedure:  Before beginning 
work with animals all personnel are required to meet all University of Mississippi 
Occupational Health and Safety Program (OHSP) standards for conducting 
research with animals. This includes submission of OHSP health forms, OHSP risk 
inventory, safety training through the Health and Safety Department (including 
chemical, biological, hazardous waste disposal, carcinogenic, and radiological), as 
well as online training courses through the University of Mississippi for working with 
rodent species. Also, all personnel are trained in the proper method for 
intraplantar injections into rodents. 
Safety Concerns (if appropriate):  Compliance with vivarium standards of dress 
will be followed by all laboratory members to assure safety of personnel and 
animals. Lab members will be trained in all procedures to be conducted within the 
lab including the specific procedures for modeling pain in rodent species.Make 
sure animal is properly restrained during injection.Make sure that animal is 
injected properly with minimal discomfort. 
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Definitions:  IPL: Intraplantar injections: injections into the footpad. 
Procedural Steps:   The animal is removed from its home cage, gently restrained in a soft 
towel.  One hindlimb is gently pulled out from the towel and is injected with a 5% formalin solution 
in the footpad (note: this is formalin and not formaldehyde).  For mice the formalin volume is 25 l 
and for rats is 50 l.  The animal is placed in an observation cage and pain-related behavior is 
observed for up to one hour.  Behaviors of interest are:  for mice: frequency and/or duration of 
soft biting/licking affected foot; for rats: frequency and/or duration of favoring, lifting and soft 
biting/licking affected foot. After the observation period the animal is returned to home cage. 
  
IPL injections of formalin at such concentrations are designed to produce a longer lasting 
nociceptive response than the acute thermal or mechanical nociceptive tests.  It should be noted 
that formalin-induced pain related behaviors diminish significantly over the course of the 1 hr 
observation period and are all but absent within a couple of hours of administration (e.g., some 
favoring can be detected at such time points).  Further, the concentrations employed do not 
produce self-mutilation nor lesions of the affected footpad.  Rodents are used only once in such 
assays are sacrificed after testing. 
Records to be Kept: Records of behaviors observed   
Identification and Emphasis of “Critical Steps” in Procedure:     Proper injection of 
formalin into the footpads of animals. 
Copies of forms to be used, drawings of apparatus, tables, figures, etc.:    n/a    
References, i.e. operating manuals, published techniques, other SOPs, etc.:       
 
Mogil JS, Wilson SG, Wan Y (2001) Assessing nociception in murine subjects. In: Kruger L, 
editor. Methods in Pain Research. Boca Raton: CRC Press. pp. 11-39. 
Sufka KJ, Watson GS, Nothdurft RE, Mogil JS (1998) Scoring the mouse formalin test: 
validation study. European Journal of Pain, 2, 351-358. 
Watson GS, Sufka KJ, Coderre TJ (1997) Optimal scoring strategies and weights for the 
formalin test in rats. Pain, 70, 53-58. 
Vierck CJ (2005) Animal models of pain. In: McMahon SB, Koltzenburg M, Wall PD, editors. 
Wall and Melzack's textbook of pain 5th ed. Edinburgh: Elsevier Churchill Livingstone. 
pp. 175-186. 
 
SIGNATURES 
Author/s: Date: 
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APPROVAL SIGNATURES 
IACUC Chair: Date: 
Attending Veterinarian: Date: 
 
 
 
 
 
 
 
 
 
SOP # _________________ 
Page  PAGE 1 of  NUMPAGES1  
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Appendix VII – Novel Compounds 
(For policy, see IACUC Policies at http://www.research.olemiss.edu/iacuc/policies) 
 
 
1. Provide compound names if known and not proprietary (optional):       
 
2. Which of the three following classes applies to the compound(s)? 
 
 In vitro or in vivo data exist and indicate no known toxicity. 
 In vitro or in vivo data exist and indicate probable toxicity – submit information with protocol 
application.  
[This information can come from testing the compound in question or compounds with similar structure. It may 
include information such as chemical class (stimulant, depressant, etc.), mechanism/site of action, or 
cytotoxicity.] 
 There are no In vitro or in vivo data available. 
 
3. Provide the literature or structure search strategy that was used to determine class:  Not possible at this 
time; compounds will need to be isolated or synthesized first. 
 
4. For each box checked in 2 above, describe and indicate your procedures for determining the following: 
 
Initial dose Route of 
administration 
Intervals for 
increasing the 
dose [e.g., half log] 
Reasons for 
deviating from the 
plan 
Rationale for 
target dose [e.g., 
adverse effects 
and/or dose needed 
to treat the disorder] 
1mg/kg i.p., p.o. log units       we will begin with 
the lowest possible 
does because of the 
nature of the 
compounds being 
tested (i.e. no prior 
in vitro or in vivo 
data).  Moreover the 
animals will be 
closely monitored to 
guard against any 
toxicity.  Further 
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doses will be 
evaluated in a dose 
response method in 
the assay.  
                              
                              
 
5. Establish a data collection procedure for monitoring animals on the treatment, and attach it to 
this protocol.   
This procedure should include an observational checklist of signs of pain and distress in the 
species in this study, and the frequency of observations to be made during the treatment 
period. 
 
6. List personnel who will monitor the animals.  Indicate the training/background that provides 
them with the expertise to do this. Lisa Wilson (Dr. El-Alfy has trained Lisa.  She has six years 
experience conducting in vivo animal experiments.) Jessica Mankus (Lisa Wilson trained 
Jessica.  She has one-year experience conducting behavioral experiments.) Dr. Murray has 14 
years experience working with rodents. Developed and perfected Millar catheterization 
procedure, trained in basic animal handling, blood, and tissue collection, arterial and venous 
catheterization, and general rodent survival surgery at East Carolina University SOM, Auburn 
University CVM, University of South Carolina SOM, and the University of Mississippi. 
 
7. Ideally, humane endpoints (predictive signs, indicators of an irreversible deteriorating 
condition) should be established prior to beginning animal work. Realizing the difficulty in 
predicting these for studies which involve compounds with unknown adverse effects, PIs 
should try to develop humane endpoints if severe pain, severe distress, or death is observed. 
Guidelines should be in place to euthanize animals 1) when humane endpoints are reached, 2) 
when the study objectives have been realized, 3) if it becomes clear that they cannot be 
realized, or 4) whenever the degree of suffering is not required or justified by the protocol. 
 
 A. Explain how animals with severe responses to treatment will be handled: Animals with 
severe distress such as shallow breathing, severe weight loss, inabilty to feed or showing 
convulstions or gasping will be euthanized. 
 
B. List the signs of pain or distress that may be severe enough to indicate the need for 
euthanization: gasping, severe weight loss, inability to feed, shallow breathing, or showing 
severe convusions. 
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C. State the method of euthanasia: Animals will be euthanized with CO2 asphyxiation and 
cervical dislocation will be used to assure death. 
 
____________________________________________________________________________________
_____________ 
All animal monitoring forms should be kept in a location accessible to the Attending Veterinarian 
and animal care staff.  The PI will notify the Attending Veterinarian in a timely manner when 
Unanticipated Significant Adverse events are observed.  The PI will complete the relevant 
monitoring sheet and submit a copy of it to the Animal Care Office in NCNPR. 
 
Include the following information in the Protocol Annual Update Form: 
(1) number of compounds used; 
(2) number of  animals used; 
(3) number of animals categorized as something other than the original pain category; 
(4) number of animals euthanized after reaching the humane endpoint. 
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Data Collection Form for Formalin Assay: 
 Instructions:  
 Record number of licking or biting of injected paw for 30 
second increments for ten minutes post formalin injection; second period of recording begins fifteen 
minutes post formalin injection, again record number of licking or biting of the injected paw in 30 second 
increments for forty-five minutes. 
 
 Protocol Number: 
 Date of test:  
Animal ID (Mouse Number) M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 
Time (minutes) 
0 to 5           
5 to 10           
10 to 15           
15 to 20           
20 to 25           
25 to 30           
30 to 35           
35 to 40           
40 to 45           
45 to 50           
50 to 55           
55 to 60           
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